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ABSTRACT 
Polyomaviruses are nonenveloped viruses with an icosahedral capsid of about 40-
45 nm in diameter. The human polyomavirus BK (BKV) is a member of the 
Polyomaviridae family detected in 1971 in the urine of an immunosuppressed renal 
transplant recipient who developed ureteric stenosis. BKV has a worldwide 
seroprevalence of about 90%. After the  primary  infection,  BKV  establishes  a  
life-long  latency  within  the  urogenital  tract.  The  severe  immunological 
impairment occurring in transplant kidney recipients leads to BKV reactivation that 
may  result  in  the  polyomavirus  associated  nephropathy  (PVAN).  During  
transplantation, kidney is  subjected  to  hypoxic  conditions,  driven by  the  action 
of Hypoxia Inducible Factor (HIF). It has been proved that HIF isoform-1α (HIF-1α) 
may interact with several viruses, but till now there are no evidences regarding  the  
interaction between BKV and HIF-1α. In the present study, we aimed to achieve a 
better understanding about the relation between BKV infection and hypoxia 
conditions in kidney cells in case of transplantation. Firstly, 17 kidney paraffin-
embedded tissue samples were collected from kidney transplant patients, who 
developed or not PVAN (PVAN and NOT PVAN group) and from a control group in 
order to evaluate HIF-1α expression levels in vivo. Total RNA was extracted from 
paraffin embedded tissues, reverse transcripted into cDNA and HIF-1α expression 
was measured by means of a qualitative Real Time PCR. Then, in vitro 
experiments were conducted using the VERO cell line to evaluate the possible 
interaction between the BKV promoter and HIF-1α. Luciferase and Chromatin 
Immunoprecipitation (ChIP) assays were performed on BKV transfected VERO 
cells, to verify the interaction between the viral promoter and HIF-1α. In parallel, to 
clarify the nature of the interaction between HIF-1α and the BKV promoter, the 
sequences were in silico analyzed using BLASTN 2.2.32+ software to find whether 
one or more hypoxia response elements (HRE) core sequences were present in 
the BKV promoters. Finally, the effect of hypoxia on BKV replication was assessed 
by evaluating BKV replication in BKV infected VERO cells, treated and not treated 
with the hypoxia mimic Cobalt Chloride (CoCl2). The HIF-1α expression level 
resulted 13.6 folds higher in PVAN tissues than in the control group while no 
differences were observed between the NOT PVAN tissues and the control group. 
Luciferase assay showed that the presence of HIF-1α stabilized the BKV promoter, 
increasing its activity from 2-folds to 6-folds (p<0.05) in transfected cells. ChIP 
assay showed a physical interaction between HIF-1α and the BKV promoter. 
BLASTN analysis showed no match between HRE sequence and the BKV 
promoter sequences, confirming that no binding sites for HIF-1α are present in the 
viral promoter. Finally, data obtained from BKV infected VERO cells revealed that 
BKV viral load was 5-fold increased in CoCl2 treated cells compared to not treated 
infected cells. These data, taken together, are significant to define the role of 
hypoxic stress in BKV replication after renal transplantation. In particular, it can be 
concluded that the replication of this opportunistic virus, mainly due to 
immunosuppressive therapy, is furthermore stimulated and favorite by HIF-1α 
activation, driven by hypoxic conditions during transplantation. The experimental 
results suggested a hypothetical molecular mechanism underling this thesis, which 
can be outlined as follows: cellular response to hypoxic environment prevents HIF-
1α proteasomal degradation, allowing the creation of a HIF-1 active complex. This 
complex translocates to the nucleus where it binds to the BKV promoter, 
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stimulating the transcription of viral genes and promoting the BKV replication. If 
confirmed by further experiments, this scenario may have important clinical 
implications: exposition to hypoxia during renal transplantation process should be 
considered as a crucial risk factor for the development of PVAN. These findings 
could be translated into clinical practice, replacing modulation of HIF system with 
ex-vivo organ preservation technologies, such as extra-corporeal membrane 
oxygenation, or considering HIF-1α as a target to be inhibited, perhaps using RNA 
interference technology. 
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SOMMARIO 
I Polyomavirus sono virus privi di envelope con un capside icosaedrico di 40-45 nm 
di diametro. Il Polyomavirus umano BK (BKV) è un membro della famiglia dei 
Polyomaviridae ed è stato isolato per la prima volta nel 1971 dalle urine di un 
paziente sottoposto a trapianto di rene, il quale aveva sviluppato stenosi 
dell’uretere. BKV è ubiquitario nella popolazione mondiale e presenta una 
sieroprevalenza del 90% circa. In seguito alla prima infezione, generalmente 
asintomatica, BKV instaura latenza nel tratto uro-genitale. Uno stato di profonda 
immunocompromissione, tipico nei soggetti sottoposti a trapianto di rene, provoca 
una riattivazione di BKV che può portare allo sviluppo della nefropatia associata ai 
polyomavirus (PolyomaVirus Associated Nephropaty, PVAN). Durante il processo 
di trapianto, il rene è soggetto ad una condizione di ipossia, modulata dall’azione 
dei fattori inducibili dell’ipossia (Hypoxia Inducible Factors, HIF). Differenti studi 
hanno dimostrato che l’isoforma 1 alpha di HIF (HIF-1α) può interagire con diversi 
virus ma, ad oggi, non esistono informazioni riguardo l’interazione tra HIF-1α e 
BKV. Lo scopo del presente studio è quello di chiarire la relazione tra le infezioni 
da parte di BKV e la condizione di ipossia nelle cellule renali in caso di trapianto. In 
primo luogo, per valutare i livelli di espressione di HIF-1α in vivo, sono stati 
reclutati un totale di 17 pazienti sottoposti a trapianto di rene, comprendenti 
pazienti che hanno sviluppato o meno PVAN (PVAN e NOT PVAN) e pazienti 
controllo. L’RNA totale è stato estratto dalle biopsie paraffinate di ciascun paziente, 
retrotrascritto in cDNA e l’espressione di HIF-1α è stata valutata mediante un 
saggio di real time PCR qualitativo. Successivamente, per valutare una possibile 
interazione tra il promotore di BKV e HIF-1α, sono stati condotti esperimenti in vitro 
sulla linea cellulare VERO. Per verificare l’interazione tra il promotore virale e   
HIF-1α sono stati condotti un saggio luciferasico e un saggio di 
immunoprecipitazione della cromatina (ChIP) su cellule VERO trasfettate con BKV. 
In parallelo, per chiarire la natura dell’interazione tra HIF-1α e il promotore di BKV, 
è stata eseguita un’analisi in silico usando il software BLASTN 2.2.32+ per 
evidenziare l’eventuale presenza nel promotore virale di una o più sequenze 
responsive all’ipossia (Hypoxia Responsive Element, HRE). Infine, è stato valutato 
l’effetto dell’ipossia sulla replicazione virale, monitorando la replicazione di BKV in 
cellule VERO infettate con BKV e trattate o meno con l’ipossia-mimetico cloruro di 
cobalto (CoCl2). L’espressione di HIF-1α è risultata essere 13.6 volte aumentata in 
tessuti PVAN rispetto al gruppo di controllo mentre nessuna differenza è stata 
osservata tra il gruppo NOT PVAN e il gruppo controllo. Il saggio luciferasico ha 
mostrato che la presenza di HIF-1α nelle cellule trasfettate stabilizza il promotore 
di BKV, incrementando la sua attività in un range compreso tra le 2 e le 6 volte 
(p<0.05). Il saggio di ChIP ha mostrato l’esistenza di un’interazione fisica tra     
HIF-1α e il promotore di BKV. L’analisi effettuata con BLASTN ha mostrato 
l’assenza di HRE nella sequenza del promotore di BKV confermando l’assenza di 
siti di attacco per HIF-1α nel promotore virale. Infine, i dati ottenuti dalle cellule 
VERO infettate con BKV, hanno mostrato che la carica virale è 5 volte aumentata 
nelle cellule trattate con CoCl2 rispetto alle cellule non trattate. Tutti questi dati, 
risultano importanti per definire un ruolo dello stress ipossico nella replicazione di 
BKV in seguito al trapianto renale. In particolare, è possibile concludere che la 
replicazione di questo virus opportunista, dovuta principalmente alla terapia 
immunosoppressiva, è oltretutto stimolata e favorita dall’attivazione di HIF-1α, 
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guidata dalle condizioni di ipossia durante il processo di trapianto. I risultati 
sperimentali suggeriscono un ipotetico meccanismo molecolare alla base di questa 
tesi, che può essere spiegato come segue: la risposta cellulare all’ambiente 
ipossico previene la degradazione proteasomale di HIF-1α permettendo la 
creazione di un complesso HIF-1 attivo. Questo complesso trasloca quindi nel 
nucleo dove si lega al promotore di BKV promuovendo la trascrizione dei geni virali 
e stimolando la replicazione di BKV. Se confermato da esperimenti futuri, questo 
scenario potrebbe avere importanti implicazioni cliniche: l’esposizione a stati di 
ipossia durante il processo di trapianto dovrebbe essere considerato un fattore di 
rischio cruciale per lo sviluppo di PVAN. Queste informazioni potrebbero essere 
traslate nella pratica clinica, sostituendo la modulazione del sistema degli HIF con 
tecnologie di preservazione dell’organo ex-vivo, come per esempio l’ossigenazione 
extra corporea, oppure considerando HIF-1α come un target da inibire usando, per 
esempio, la tecnologia dell’RNA interference. 
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1. INTRODUCTION 
1.1 HUMAN POLYOMAVIRUS BK 
The human polyomavirus BK (BKV) is a member of the Polyomaviridae 
family detected in 1971 in the urine of an immunosuppressed renal 
transplant recipient who developed ureteric stenosis; the new virus was 
named as the initials of the patient BK [Gardner et al., 1971]. Polyomavirus 
are nonenveloped virus with an icosahedral capsid of about 40-45 nm in 
diameter. BK virions consist of 88% proteins and 12% DNA. BKV and the 
strictly related JC polyomavirus (JCV) were the first human viruses isolated 
that strongly resembled the morphology and genomic organization of the 
previously described oncogenic polyomaviruses simian virus 40 (SV40) and 
mouse polyomavirus. The viral genome is composed by a single copy of a 
circular double-stranded DNA [Khalili and Stoner, 2001]. Primary infection 
occurs predominantly during childhood and after the primary infection, often 
asymptomatic, it establishes a life-long subclinical latency mostly within the 
kidney, the urogenital tract and probably also in B lymphocytes and other 
locations in immunocompetent individuals [Dörries et al.,1997; Shah 1996; 
Dolei et al., 2000; Dörries et al.,1994]. Intermittent or chronic BKV 
reactivation can occur in individuals with perturbed immune conditions 
leading to different symptomatology with different degrees of severity. For 
these reasons, during the recent years, BKV has drawn the attention of the 
scientific and medical communities because of its potential to cause human 
diseases.  
1.1.1 GENOME 
BKV genome consists of a single copy of circular double-stranded DNA 
molecule of about 5 kilobase pairs. BKV genome can be divided into three 
functional regions: the genetically conserved early and late regions and a 
hypervariable regulatory region called Non Coding Control Region (NCCR) 
that contains the bidirectional promoter for both the early and late regions 
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[Cole et al., 2001; Moens et al., 2001]. The early region encodes for the 
three viral regulatory proteins: the large tumor antigen (TAg), the small 
tumor antigen (tAg). The late coding region, expressed only after the 
initiation of DNA replication, contains the genetic information for the major 
capsid viral protein 1 (VP1) and the two minor viral capsid proteins 2 and 3 
(VP2 and VP3) and for a small protein called agnoprotein (figure 1). 
 
Figure 1. Schematic representation of the functional organization of BKV genome  
[http://www.hindawi.com/journals/jir/2013/373579/fig2/] 
1.1.2 NON CODING CONTROL REGION 
The NCCR is the genome sequence that contains the origin of replication 
and the sequences involved in the transcriptional regulation of both early 
and late genes. The NCCR sequence has been arbitrarily divided into four 
transcription factor binding sequence blocks, called O (142bp), P (68bp), Q 
(39bp), R (63bp) and S (63bp). The liner configuration is defined as the 
archetypal strain (WW) (figure 2).  
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Figure 2. BKV sequence blocks [Liang et al.,2012] 
The NCCR displays an higher degree of variability than that displayed in 
the other regions of the genome. This variations are due to deletions, 
duplications and other rearrangements and were determined after several 
cell culture passages. In particular, duplication of P-block sequence, and  Q 
and R blocks completely deletion (O142-P68-P1-7;26-68-P64-S63), are typical of 
the Dunlop strain, widely used for in vitro experiments. It has been shown 
that the BKV Dunlop strain grows well in human embryonic kidney (HEK), 
Vero and human umbilical vein-vascular endothelium cells (HUV-EC-C) 
[Seif et al., 1979]. Also naturally occurring NCCRs variants show 
duplication or triplication of the P region including portion of the 
neighbouring Q region. Likewise, deletions are found to occur anywhere 
within the P, Q, R and S regions. Several in vivo evidences demonstrate 
that even if the archetypal conformation is the most prevalent in patients 
and healthy subjects, BKV with rearranged NCCR is present in 
cerebrospinal fluid from patients with neurological complications [Bárcena-
Panero et al., 2012], in the plasma of renal transplant patients [Gosert et 
al., 2008], in subjects affected by polyomavirus-associated nephropathy 
(PVAN) [Azzi et al., 2006; Randhawa et al., 2003] and AIDS patients (table 
1) [Jorgensen et al., 2003]. Correlations between NCCR rearrangements 
with transcriptional activity and transformation efficiency have been well 
studied. Rearrangements in the NCCR can remove, create or increase the 
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number of transcription factor binding sites creating variation in the 
replication and the transcription of the virus genome [Moens et al., 1995a]. 
ISOLATE REFERENCE SOURCE 
Gardner Gardner et al., 1971 renal transplant patient 
Dunlop Seif et al., 1979 renal transplant patient 
MG Lecatsas et al.,1976 renal transplant patient 
SB Gibson and Gardner, 1983 patient with lymphoma, England 
AS Coleman, 1980 pregnant woman 
DB Tavis et al., 1990 bone marrow transplant patient 
BO Borgatti et al., 1981 immunosuppressed children, Italy 
WW Rubinstein et al., 1987 immunocompetent patient 
Table 1. list of some BKV strains and sources from which the strains have been 
isolated 
1.1.3 EARLY REGION 
The early region is a functional region of the genome that encodes for the 
regulatory proteins TAg and tAg, which are products of two alternatively 
spliced mRNAs. In 1989 Bollag and colleagues reported the existence of a 
third form of BKV tumour antigen, called truncated tumour antigen 
(truncTAg), that was presumed to be a proteolytic degradation product of 
the TAg [Bollag et al., 1989]. In 2009 Abend and colleagues presented 
evidences about the expression of the truncTAg, encoded from an 
alternatively spliced mRNA derived from the excision of a second intron 
from the mRNA encoding TAg [Abend et al., 2009]. The early region is 
expressed during the early stages of the viral life cycle and can be 
expressed later during infection, after the onset of viral DNA replication. 
TAg is a multifunctional protein of 695 amino acids  involved in DNA 
replication and transcription. The ability of BKV to transform cells is due to 
its capability to deregulate the cell growth control as a means to drive 
resting cells into S phase, in which DNA replication is maximized. The 
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major transformation domains have been well defined in the N-terminal and 
C-terminal of the TAg sequence [Ahuja et al., 2005]. These are: the N-
terminal J domain that interacts with the heat shock cognate 70 (Hsc70) co-
chaperone protein [Campbell et al., 1997; Kelley and Georgopoulos C, 
1997], the N-terminal retinoblastoma protein (pRb) binding domain contains 
a conserved LXCXE motif throught which TAg associates with pRb and its 
family members, p107 and p130 [DeCaprio et al., 1988, Harris et al., 1996] 
and the C-terminal bipartite p53 binding region [Cavender et al., 1995; 
Kierstead and Tevethia 1993; Li et al., 2003]. Through its N terminus, TAg 
also interacts with two other proteins that are involved in cell growth control, 
the E3 ubiquitin ligase, CUL7 and the mitotic spindle checkpoint protein, 
Bub1 [Ali et al., 2004; Cotsiki et al., 2004; Kohrman and Imperiale, 1992].  
tAg is generated by an alternative splicing of the early transcript that 
generates a Cys-rich protein composed of 172 residues, located both in the 
nucleus and the cytoplasm. TAg and tAg share the amino-terminal 82 
amino acids and contain different carboxy-terminal regions. tAg is 
composed by a N-terminal J domain and a C-terminal unique domain. The 
protein shares its N-terminal 78 residues with the N-terminal sequence of 
TAg, including the region of the J domain [3,31,32 Cho]. Study about tAg of 
SV40 showed that it exhibits an α-helix structure with two zinc-binding sites. 
The J domain contains three helices and has a structure similar to the J 
domain of SV40 TAg. The unique domain is composed of four helices and 
three of these helices are directly involved in the interaction with two zinc 
ions. The J and unique domain have an interface that is mostly 
hydrophobic. Considerably fewer studies have been aimed at 
characterizing the role of tAg in virus multiplication compared to TAg 
[Moens et al., 2007]. The major recognized role is to provides a helper 
function for TAg by augmenting the viral replication and trans-activation of 
the viral promoter, resulting in increased virus yeld in permissive cells 
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[Moens et al., 2001; Rundell at al., 2001]. Indeed, tAg seems to exert its 
effect by inhibition of the heterodimeric holoenzyme protein phosphates 2A 
(PP2A), a family  of abundantly expressed serine-threonine phosphatases 
implicated in the regulation of many cellular processes, including regulation 
of different signal transduction pathways and cell cycle progression [Arroyo  
et al., 2005; Sontag et al., 2006]. 
1.1.4 LATE REGION 
The late region encodes for three structural capsid proteins VP1, VP2 and 
VP3, generated from a common precursor mRNA by alternative splicing, 
and for a small protein called agnoprotein.  
VP1, VP2 and VP3 consist of 351, 232 and 362 residues respectively and 
each protein contains three functional domains that facilitate the packaging 
of the complete virus particle: 
The Nuclear Localization Signal (NLS), important to mediate the 
transport of the capsid proteins to the nucleus after their expression in the 
cytoplasm. It has been shown that BKV VP1 contains the same amino 
terminal motif that has been demonstrated to be sufficient for SV40 VP1 
targeting to the nucleus [Wychowski et al., 1986]. 
The DNA-binding domain. It has been shown that VP1, VP2 and VP3 
bind viral and non-viral DNA [Clever et al., 1993]. The DNA binding domain 
in SV40 VP1 has not been mapped yet, but SV40 VP1, in its carboxyl-
terminal extremity, contains a domain of 40 amino acids that are sufficient 
to bind double stranded as well as single stranded DNA. It has been 
demonstrated that 31 of these amino acid residues are conserved in BKV 
VP2 and VP3, suggesting that these two proteins can also associate with 
DNA [Chang et al., 1993] 
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Protein-protein interaction domain: residues 222-234 of SV40 VP3 
represent a VP1 interaction domain [Gharakhanian et al., 1988]. This 
region is 80% conserved in BVK VP3. 
The Agnoprotein is a 70 amino acids long polypeptide that predominantly 
resides in the cytosol and in the perinuclear region in association with the 
outer nuclear membrane, but a minor fraction of the protein can also be 
detected in the nucleus [Nomura et al., 1983; Okada et al., 2001; Khalili et 
al., 2005]. It is know that a particular BKV strain (strain AS) encoding a N-
terminal modified agnoprotein that can be successfully propagated in cell 
culture while, BKV variants with deleted agnogene, were detected in the 
urine of renal transplant patients [Tavis et al., 1989; Olsen et al., 2006]. 
From studies about the JCV genome is known that the agnoprotein can 
bind the TAg but the biological relevance of this interaction is poorly 
understood. The hypothesis is that agnoprotein repressed both basal and 
TAg-mediated late transcription and viral DNA replication [Safak et al., 
2001]. Whether agnoprotein influences the transforming ability of TAg is not 
known.   
1.1.5 CAPSID 
The tertiary structure of the major capsid protein VP1 can be divided into 
three modules: a N-terminal arm, an anti-parallel β-sandwich with jelly-roll 
topology and a long C-terminal extension [Liddington et al., 1991; Stehle et 
al., 1996] (figure 3). The first 15 residues of the N-terminal arm are 
probably involved in the interaction with the virus genome. The different β-
strands are connected by elaborate loops protruding outward the structure 
of the β-sandwich itself. The loops, that also contain α-helix structures, 
have been named BC, DE, EF, GH and HI. The BC, DE and HI closely 
interact at the outward end of the β-sandwich. The BC loop can be divided 
into two smaller loops: BC1 and BC2. The long EF loop forms a small jelly-
roll structure on the side of the β-sandwich. The C-terminal arm can be 
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divided into three segments: the “C helix” residues, the “C insert” and the 
“C loop”. The C-terminal arm mediates the binding between the VP1 
pentamers. 
 
Figure 3. Richardson diagram of the SV40 VP1 subunit [Liddington et al., 1991] 
The complete amino acid sequence of the BKV VP1 is reported (figure 4). 
The loops are shown, as well as the different β-strands, β-helices, the N-
terminal and the C-terminal arms. Based on amino acid comparison, it has 
been shown that the VP1 sequence of BKV is divergent from the sequence 
of other polyomaviruses primarily in the region forming the extracellular 
loops and is relatively conserved in the β-sheet framework. 
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Figure 4. Amino acid sequence of the BKV major capsid protein VP1 
The three-dimensional structure of both SV40 and murine polyomavirus 
has been determined [Liddington et al., 1991; Griffith et al., 1992]. Based 
on the similarity of their gene organizations as well as their high sequence 
homology, the solved crystal structure of SV40 VP1 has been used as a 
template to create a model of the BKV capsid structure. In 2003 a three-
dimensional model of the BKV capsid has been created by analysing 
through electron microscopy the structure of BKV virus-like particles 
generated using recombinant baculoviruses [Li TC et al., 2003; Nilsson et 
al., 2005]. The results basically confirm the high similarity between the 
SV40 and the BKV capsid structure. The predicted structure of the BKV 
capsid consists of 72 capsomers of VP1 centred on the vertices of a T=7 
icosahedral surface lattice. A single copy of either VP2 or VP3 is 
associated with each capsomer. The VP1 capsomer is built as a ring of five 
VP1 monomers, tightly linked by interacting loops between the framework 
of β-strands. The connection between the pentamers within the virion is 
allowed by the C-terminal domain of each VP1 monomer that forms an 
extended arm, which interacts extensively with subunits of the neighbouring 
pentamers, thereby tying the pentamers together in the virion shell. Each 
pentamer receives five invading arms, one from each of five other 
pentamers, and donates five arms to surrounding pentamers (figure 5 a,b). 
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Twelve of the 72 pentamers that form the capsid structure are surrounded 
by five other pentamers, while the remaining 60 are surrounded by six 
pentamers. There are three different kinds of pentamer-pentamer 
interaction: a three-fold cluster and two different two-fold clusters. 
Therefore, according to the different interpentamer bounding environments, 
the monomers that build up the pentamer can be divided into subunits α, 
α’,α’’, β, β’ and γ. α, α’, and α’’ form a a three-fold interaction, β and β’ form 
one kind of two-fold interaction, while γ forms another kind of two-fold 
interaction, while γ forms another kind of two-fold interaction (figure 5 c). 
Calcium ions seem to play an important role in viral assembly [Brady et al., 
1977], while disulfide bonds are thought to be involved in maintaining the 
stability of polyomavirus capsid [Chen et al., 2001].  
 
Figure 5. Schematic representation showing the way the C-terminal arm of each 
monomer ties the pentamers together (a,b). Overall view of SV40 virion. The six 
unique monomers are indicated and the icosahedral symmetry axis 5, 3 and 2 are 
indicated (c) [Liddington et al., 1991] 
1.1.6 LIFECYCLE 
The lifecycle of polyomaviruses can be arbitrarily divided into early and late 
stages. The early stage begins with the attachment of the virus to the 
surface of the host cell and continues until the onset of viral DNA 
replication. The late stage of infection extends from the onset of viral DNA 
replication to the end of the lytic lifecycle (figure 6). 
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Figure 6. Polyomavirus lifecycle 
Adsorption: infection of permissive cells is initiated by binding of the virion 
to specific cell surface receptors. The efficient entry of BKV requires the 
interaction between virus and cell surface sialic acids. A study conducted 
by Dugan and colleagues demonstrated that a N-linked glycoprotein with 
α(2,3)-linked sialic acid mediates productive BKV attachment and entry into 
host cells [Dugan et al., 2005]. In vitro experiments have demonstrated that 
JCV requires N-linked glycoprotein containing terminal α(2,6)-linked sialic 
acid to successfully infect the human glial cells [Liu et al., 1998].  
Entry, intracellular trafficking and uncoating: after the initial binding to their 
host cell, viral capsids are internalized by caveolae-mediated endocytosis 
[Eash et al., 2004; Anderson et al., 1996] and are transported to the 
nucleus, where the DNA is uncoated. After the entry into the cell, BKV is 
transported through the cytosol to the nucleus. The active cytoskeletal 
transport machinery plays an important role in this intracellular migration 
[Dohner and Sodeik, 2005]. Most studies indicated that the uncoating of 
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polyomaviruses occurs within the nucleus [Drachenberg et al., 2003; 
Nakanishi et al., 1996] and that virion particles enter the nucleus through 
the nuclear pore complex [Clever et al., 1991]. 
Early mRNA transcription, processing and translation: once virions have 
been uncoated, the viral minichromosome is used by RNA polymerase II as 
a template for transcription to produce early viral mRNAs. The T antigens 
are generated by alternative splicing of the same precursor mRNA. 
DNA replication: subsequent to early transcription and synthesis of the viral 
regulatory proteins there is the switch to DNA replication. A major role for 
initiation of DNA replication is played by T-Ag, which binds to specific 
sequences within the origin of replication and promotes the unwinding of 
DNA thanks to its helicase activity. T-Ag promotes the bi-directional 
replication of DNA also by recruiting all the cellular proteins that are directly 
involved in the cell DNA synthetic process and by binding the replication 
protein A (RPA), that is a single-stranded DNA binding protein important for 
an efficient DNA replication [Melendy and Stillman, 1993].  
Late mRNA transcription, processing and translation: once the viral DNA 
has been synthesized, T-Ag promotes the repression of early gene 
transcription and the progression of the virus to the late phase of its 
lifecycle, by activating the transcription of late genes. Virion proteins VP1, 
VP2, VP3 are synthesized in the cytoplasm of infected cells and 
transported to the nucleus for assembly into virions. Sequences near the 
amino terminus of VP1 and near the carboxyl-termini of VP2 and VP3 are 
essential for this nuclear accumulation [Wychowski et al., 1986; Moreland 
and Garcea, 1991]. These proteins may be transported to the nucleus as a 
complex as well as separately [Barouch and Harrison, 1994].  
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Virion assembly and release: once in the nucleus, VP1, VP2 and VP3 
assembly into the typical capsid structure made up of 72 VP1 pentamers 
with one of the two minor proteins lying in the centre of each pentamer. The 
viral minichromosome, packaged with histones, is then inserted into the 
capsids [Sandalon et al., 1997].  It has been speculated that progeny 
virions are released by lytic disruption of their host cells. However, electron 
microscopy observations showed that SV40 virions are released directly 
from the plasma membranes of intact epithelial cells [Clayson et al., 1989]. 
Therefore, it remains to be elucidated whether cell lysis or at times 
intracellular vescicular transport is the preferred pathway for the release of 
polyomaviruses progeny virions. 
1.1.7 BKV SUBTYPES DISTRIBUTION  
BKV strains are classified into four subtypes using serological and 
genotyping methods [Knowles et al., 2001]. The first studies on the 
evolution of BKV have been hampered by the limited availability of BKV 
genomes from various human populations worldwide. In the last years, the 
introduction of the sensitive polymerase chain reaction (PCR) and the 
discovery that BKV DNA sequences could be amplified also from the urine 
of non- immunocompromised subjects, allowed to conduct a series of 
evolutionary studies on the BKV subtypes’ distributions. In 1993, Jin and 
colleagues PCR-amplified and sequenced a 287 bp VP1 region, designed 
as the “typing region” , that contains a possible epitope region responsible 
for serological discrimination among subtypes, and the resultant sequences 
were used to detect subtypes-specific single nucleotide polymorphisms 
(SNPs) [Jin et al., 1993]. These sequence variations within this region have 
been used to classify BKV subtype strains in various laboratories. BKV 
isolates worldwide are classified into four subtypes (I–IV) [Knowles et al., 
2001]. Subtype I (the most prevalent subtype) has been further divided into 
four subgroups (Ia, Ib-1, Ib-2, and Ic) (table 2) [Takasaka et al. 2004; 
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Nishimoto et al. 2006; Ikegaya et al. 2006; Zheng et al. 2007]. Interestingly, 
each of these subgroups has a unique geographic distribution pattern: Ia is 
prevalent in Africa, Ib-1 in Southeast Asia, Ib-2 in Europe, and Ic in 
Northeast Asia [Takasaka et al. 2004; Ikegaya et al. 2006; Zheng et al. 
2007]. Recently it appears that a prototype of subtype I (probably emerging 
in Africa) diverged into various subgroups with the divisions of human 
populations that occurred after out-of-Africa migrations. In contrast, subtype 
IV (the second most prevalent subtype of BKV) shows a geographic 
distribution biased toward areas other than Africa, i.e., Europe and Asia 
[Zheng et al. 2007]. This finding may suggest that subtype IV originated 
outside Africa, although it is also possible that the original proportion of 
subtype IV might have been high in Africa but decreased thereafter, due to 
a change in the host susceptibility to subtype IV BKV.  
 
Table 2. BKV subgroups defined by nucleotide polymorphism [Ikegaya et al., 2006] 
1.1.8 SEROEPIDEMIOLOGY 
Serological surveys have shown that BKV infections are widespread in the 
general population with type-specific antibodies detectable in 60–80% of 
healthy adults [Taguchi et al., 1982; Knowles et al., 2003; Egli et al., 2009; 
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Antonsson et al., 2010]. Primary BKV infection occurs in early childhood. 
After primary infection, it persists in renal tissue, and probably also in B-
lymphocytes and other locations [Dolei et al, 2000; Dörries et al.,1994]. 
Natural BKV transmission is not resolved, but likely occurs via the 
respiratory or fecal-oral route [Hirsch et al., 2003]. Primary infection is 
generally asymptomatic, and no definite clinical presentations have been 
attributed, although fever and non-specific upper respiratory symptoms 
have been suggested [Reploeg et al., 2001]. However, reactivation of these 
viruses in immunocompromised patients with relative or absolute cellular 
immunodeficiency has been associated clearly with serious complications 
[Major et al., 2001]. BKV reactivation is associated with interstitial nephritis 
[Nickeleit et al., 2000] and ureteral stenosis in renal allograft recipients, and 
late onset haemorrhagic cystitis in bone marrow transplant patients [Major 
et al., 2001]. BKV has also been detected in a variety of tumors such as the 
carcinoma of the urinary tract, prostate cancer and neuroblastoma 
renewing the interest about the BKV epidemiology [Carluccio et al., 2014; 
Flaegstad et al., 1999]. Reactivation of BKV may also occur up to 60% in 
healthy people in state of pregnancy, older age or immune dysfunction, 
leading to asymptomatic viruria [Hirsch 2005; Tsai et al., 1997; Kitamura et 
al., 1990]. Kean and colleagues demonstrated that BKV seroprevalence 
has an age specific trend from childhood to adulthood providing important 
data regarding the prevalence and the age-related timeline for infection 
(figure 7) [Kean et al., 2009]. Seroepidemiological studies, combined with 
virological and clinical data (i.e. the high prevalence of infection, low 
morbidity, asymptomatic reactivation and host specificity) suggested 
coevolutionary adaptation of BKV and the human host [Hirsch and Steiger 
2003] and results therefore useful in determining past and current BKV 
exposure in patients at risk of BK-associated diseases or showing early 
signs of complications due to polyomavirus reactivation [Stolt et al., 2003].   
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Figure 7. BKV seroprevalence [Kean et al., 2009] 
1.2  POLYOMAVIRUS ASSOCIATED NEPHROPATHY (PVAN) 
PVAN is one of the most common viral complication in renal transplant 
recipients and is an increasingly recognized cause of renal transplant 
dysfunction and graft loss [Costa and Cavallo, 2012]. PVAN characteristic 
were first described in 1978 by Mackenzie and colleagues as evidence of 
stenosis of the transplant ureter with virus infected cells in the ureteric 
epithelium and in one case also in the renal tubules [Mackenzie et al., 
1978]. In 1995, Purighalla and colleagues first recognized and described 
PVAN as a serious complication after renal transplantation [Purighalla et 
al., 1995]. Since the first description of PVAN in 1995, an increasing 
prevalence rate from 1% to 10% has been evidenced [Hirsch et al., 2006]. 
The increase in prevalence data could be due to the introduction of new 
deeply immunosuppressive drugs and/or the relative decline in acute 
rejection rates. PVAN can lead to kidney graft loss in 10% up to 100% of 
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the cases, determining the return in hemodialysis, thus significantly and 
markedly reducing the graft survival.  
1.2.1 CLINICAL AND HISTOLOGICAL  FEATURES 
PVAN clinical presentation may be inconspicuous and lacks of useful 
features. Varying degrees of renal dysfunction may be seen, although in 
early stages even normal serum creatinine levels may be detected. PVAN 
may consist in interstitial nephritis and/or ureteric stenosis with ureteric 
obstruction, hydronephrosis, and sometimes associated urinary tract 
infections [Costa and Cavallo, 2012]. Most of the cases are preceded by an 
asymptomatic phase of persistent and significant viruria. Sustained BKV 
viruria is typically followed within few weeks by viremia. A significant and 
sustained viremia identifies patients with uncontrolled viral replication 
potentially leading to parenchymal injury. Progression of PVAN leads to 
eventual deterioration of the kidney graft function. Usually, appearance of 
viruria and viremia precedes the increase in serum creatinine by weeks or 
months. Once the virus has reactivated, an ascending infection via cell-to-
cell spread occurs [Meehan et al., 2006; Drachenberg et al., 2003; Nickeleit 
et al., 2000(a)]. Without appropriate immunologic control, a progressive lytic 
infection occurs resulting in large nuclear and perinuclear virus-containing 
inclusions in the tubule cells [Low et al., 2004; Bhol et al., 2007].  The 
infected cells have an enlarged nucleus with a gelatinous basophilic 
inclusion resulting from accumulation of the newly formed virions 
[Drachenberg and Papadimitriou, 2006]. Lysis of the infected cells results in 
viral seepage into the tubule lumen and urine but also to the interstitium 
and propagation to surrounding cells.  Subsequent tubular cell necrosis 
leads to cast formation and denudation of the basement membrane. 
Destruction of tubular capillary walls results in vascular spread of the virus. 
A heterogeneous interstitial infiltration of inflammatory cells as well as 
tubulitis may be absent, intermixed with the active infection, or noted in 
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areas that lack cytopathic changes. Collateral damage with necrosis and 
apoptosis of noninfected tubule cells may occur. The resultant effect of 
continued intragraft inflammation, tubular injury, and upregulation of 
profibrotic mediators is allograft dysfunction and loss (figure 8). 
   
Figure 8: renal biopsies of a 62 years old man at 5 months from transplantation 
and 4 months before the starting of anti-graft loss therapy. A. Periodic acid–Schiff 
stain shows areas of tubular inflammation, focal tubular basement membrane 
disruption (arrow), and interstitial inflammation consisting of lymphocytes, plasma 
cells, and histiocytes affecting 30% of the total sampled renal parenchyma. B. 
Immunohistochemical staining for  SV40 large T antigen shows numerous 
positively staining nuclei in tubular epithelial cells (arrow) in areas of less severe 
interstitial and tubular inflammation, indicating active polyomavirus infection 
Original magnification X400) [Wiseman, 2009] 
1.2.2 VIROLOGICAL SCREENING 
The pathogenesis of PVAN probably involves the interaction of multiple risk 
factors, which include immunosuppression and determinants of the patient, 
the transplanted organ, and the virus. Patient determinants increasing the 
risk for PVAN may include increased older age and male gender [Ramos et 
al., 2002; Awadalla et al., 2004; Wong et al., 2003; Trofe et al., 2003; 
Dadhania et al. 2004; Celik et al., 2003; Barri et al., 2001; Trofe et al., 
2003(a)], white ethnicity [Ramos et al., 2003, Trofe et al., 2003(a)], diabetes 
mellitus [Randhawa et al., 1999; Trofe et al., 2003(a); Nickeleit et al., 1999] 
and a negative BKV serostatus in pediatric recipients [Ginevri et al., 2003; 
Smith et al., 2004]. However, a positive BKV serostatus prior to 
transplantation does not protect against polyomavirus replication, viremia or 
A B 
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PVAN [Hirsch et al., 2002; Brennan et al., 2005]. Viral replication is the 
single common feature of all patients at risk of nephropathy. In a kidney 
transplant recipient, BKV reactivation can come from the donor or the 
recipient. Recipients who had BKV infection and received a kidney from the 
same donor have been shown to have identical BKV genotypes, supporting 
donor transmission [Bohl et al., 2005; Vera-Sempere et al., 2006]. 
Recipients whose donors had higher BKV antibody titers were more likely 
to develop BKV infection than those with lower titers, also supporting donor 
transmission [Bohl et al., 2005; Andrews et al., 1988]. Injury is also believed 
to contribute to reactivation. Therefore, screening for viral replication is the 
most useful tool for the identification of patients at risk of developing 
nephropathy, thus allowing for earlier intervention, in particular a 
prevemptive reduction of immunosuppression, with improvement of 
outcome [Costa and Cavallo, 2012]. Screening for polyomavirus replication 
presents a high negative predictive value (>99%), as in the absence of 
virus replication PVAN is excluded [Mischitelli et al., 2007; Cavallo et al., 
2009]. Screening for viral replication is also the most important tool for 
monitoring the response to treatment in patients with diagnosed PVAN. 
Different screening assays are available: 
1) urine cytology, i.e. detection of epithelial cells termed “decoy cells” that 
are present in 40-60% of transplant recipients, although it is a good 
screening test with a negative predictive value (NPV) of 100%, positive 
predictive value (PPV) is very low (about 20%) [Hariharan et al., 2006]; 
2) quantification of urinary BKV-DNA, with a load 100-fold higher than 
plasma values evidenced in 30-40% of transplant recipients, that has a 
PPV of approximately 40% [Hariharan et al., 2006]; 
3) quantification of plasma BKV-DNA, with a viral load >104 copies/mL 
recommended for a presumed diagnosis of PVAN [Hirsch et al., 2005; 
Marchetti et al., 2007; Smith et al., 2007]; 
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4) quantification of urinary VP1 mRNA that is likely to mirror active viral 
replication. 
Considering that viral inclusions may be absent in the early stages of 
PVAN, inflammation may be scarce and the focal nature of renal 
involvement, the quantification of polyomavirus DNA on renal graft biopsies 
and/or ureteral specimens could also be taken into account besides 
histopathological evaluation. Polyomavirus-DNA quantitation could be 
useful in the presence of little evidence of viral cytopathy [Schmid et al., 
2005]. The limited sensitivity of allograft biopsy is also critical for the 
definition of “resolved PVAN” as the goal of any intervention. Resolution of 
PVAN not only requires the disappearance of the histological signs of 
active disease (i.e., viral replication, inclusions, necrosis, inflammatory 
infiltrates) and negative immunohistochemistry, but should also include 
negative results of the surrogate replication markers such as BKV viremia 
and viruria. 
1.2.3 DIAGNOSIS 
PVAN is typically diagnosed within the first year post transplantation, 
although approximately 25% of the cases are seen later. When BKV 
nephropathy is diagnosed early within the first 6 months after 
transplantation and the creatinine is stable, survival is improved compared 
with when the diagnosis is made later and the creatinine is elevated. The 
definitive diagnosis of PVAN is made by histopathologic evaluation, 
however this form of diagnosis presents some drawbacks, including limited 
sensitivity due to focal involvement, thus accounting for sampling errors; 
varying presentations with cytopatic-inflammatory and/or fibrotic/scarring 
patterns; difficult differential diagnosis from acute rejection, that may 
coexist with an opposite impact on intervention strategies [Costa and 
Cavallo, 2012]. The diagnosis and the severity of BKV infection correspond 
to our understanding of the pathogenesis of nephropathy. Viral replication 
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begins early after transplantation and progresses through detectable 
stages: viruria then viremia then nephropathy (figure 9) [Hirsch et al., 2002; 
Brennan et al., 2005(a); Bressollette-Bodin et al., 2005; Limaye et al., 2001; 
Nickeleit et al., 2000]. Viruria can be detected by PCR for BKV DNA, 
reverse transcription PCR for BKV RNA, cytology for BKV inclusion bearing 
decoy cells, or electron microscopy for viral particles [Hirsch et al., 2002, 
Gardner et al., 1984,Brennan et al., 2005; Ding et al., 2002]. These tests 
are sensitive for detecting active BKV infections but lack specificity for 
nephropathy because the detected virus could originate anywhere along 
the urinary tract. Detection of BKV DNA in the plasma or viremia may be a 
better indicator of nephropathy. As the infection intensifies, the markers of 
viral replication increase. Threshold values have been suggested to predict 
BKV nephropathy, but considerable overlap of these values exists among 
recipients without BKV nephropathy, active BKV nephropathy, and solved 
BKV nephropathy [Randhawa et al., 2004]. Considering the main 
pathogenic factors of PVAN, i.e., viral replication and failure of immune 
surveillance, early diagnosis may be accomplished by virological and viro-
immunological monitoring, consisting in monitoring of viral replication and 
evaluation of virus-specific immune response, respectively.  
 
Figure 9: Type and prevalence of BKV infections in kidney transplant recipients 
[Bhol et al., 2007] 
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1.2.4 TREATMENT 
The treatment of PVAN has three fundamental objectives: to eliminate the 
virus, to avoid the development of acute rejection, and to preserve the renal 
function [Cavallo et al., 2009]. At the moment, there is no approved and 
defined treatment for PVAN. The main line of intervention consist in 
reducing immunosuppression. This can be accomplished by three different 
approaches: reducing, stopping or switching the immunosuppressive drugs 
employed. More recently, the use of the immunomodulant agent 
leflunomide, together with the reduction of immunosuppression has been 
proposed. As the majority of cases of PVAN have been associated to triple 
immunosuppressive therapy including combinations of calcineurin inhibitors 
(tacrolimus, cyclosporine A), antiproliferative agents (mycophenolate 
mofetil, azathioprine) and corticosteroids, most of recommended strategies 
includes decreasing, switching or stopping the ongoing treatment [Costa 
and Cavallo, 2012]. Reduction of immunosuppression may prove 
insufficient to control viral replication or may not be appropriate in patients 
at high risk of rejection. Antiviral agents have been used, but no defined 
treatment is recommended and results are controversial. On the basis of in 
vitro activity against BKV, cidofovir, quinolones, and intravenous Ig (IVIG) 
have been reported as treatment options for BKV nephropathy. Cidofovir is 
a cytosine analogue and viral DNA polymerase inhibitor of BKV replication, 
but the mechanism is unclear because BKV lacks a viral polymerase gene 
[Farasati et al., 2005; Andrei et al., 1997; De Clercq et al., 2003]. Rather 
than a direct effect on BKV replication, cidofovir may restore the function of 
p53 and pRb, targets of the large T antigen, and permit BKV-infected cells 
to undergo apoptosis [Akan et al., 2006; De Clercq et al., 2003]. Despite 
this evidence, actually there is no randomized controlled study on the 
immusuppressive drugs and no selective antiviral target. The prevention of 
PVAN by regular monitoring of viremia/viruria remains the most appropriate 
approach and may prompt a preemptive reduction of immunosuppression. 
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1.3  HYPOXIA INDUCIBLE FACTOR 
Hypoxia is defined as a reduction of oxygen amount available to a cell, 
tissue or organism. Oxygen deprivation creates significant stress in living 
cells linked to inappropriate accumulation of free radicals, which cause 
additional stress on proteins and DNA in the cell. The decline of oxygen 
level can also cause alteration in gene transcription or may result in 
posttranslational modifications of proteins, leading to changes of cell 
metabolism. Cells temporarily arrest in the cell cycle, reduce energy 
consumption and secrete survival and proangiogenic factors. The cellular 
response to hypoxia is focused on addressing the energy deficit created by 
the decrease in available oxygen. When aerobic metabolism is diminished 
due to the lack of molecular oxygen, cell utilizes the hypoxia inducible 
factors (HIFs) signaling cascade that drives the expression of a wide variety 
of genes essential for the adaptive response to hypoxia. HIFs are the 
master regulators of oxygen homeostasis and play a role in the 
development, postnatal physiology as well as disease pathogenesis. Since 
then, more than 70 targets genes regulated directly by HIFs have been 
identified and expression of over several hundred genes are known to be 
directly or indirectly influenced by HIF.  
1.3.1 STRUCTURES AND ISOFORMS 
HIF is a dimer composed of 120 kDa oxygen-regulated α-subunit and the 
constitutively expressed 91-94 kDa β-subunit (also known as the aryl 
hydrocarbon receptor nuclear translocator, ARNT). In mammals there are 
three isoform of the HIF-1α subunit (HIF-1α, HIF-2α also known as EPAS1 
and HIF-3α or IPAS) and three isoform paralogues of HIF-1β (Arnt1, Arnt2 
and Arnt3) [Zagorska and Dulak, 2004]. HIF-1α and HIF-2α are the best 
understood and described [Loboda et al., 2010, Majmundar et al., 2010]. 
HIF1 is the principal regulator of the hypoxic response in the mammalian 
cells [Semenza et al., 1998] and in particular, HIF-1α is recognized to 
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control more than 100 genes and this suggested that in endothelial cells 
more than 2% of all human genes may both directly or indirectly regulated 
by this factors [Manalo et al., 2005]. The role of HIF-3α is less well 
understood, but it is has been suggested that the alternative splice form of 
HIF-3α binds to and inhibits the transcriptional activity of HIF-1α [Makino et 
al., 2001]. HIF-2α has a similar structure to HIF-1α but the pattern of their 
expression varies: HIF-1α is widely  present while HIF-2α is expressed only 
in certain tissues [Wiesener et al., 2003]. In particular, HIF-2α and HIF-3α 
are selectively expressed in vascular endothelial cells, type II pneumocytes, 
renal interstitial cells, liver parenchymal cells and cells of the myeloid 
lineage [Bertout et al., 2008]. Both α and β subunits are member of the 
family of the basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) 
domain-containing transcription factors [Wang et al., 1995]. Apart from 
those domains, which are important for DNA binding and dimerization, a 
central oxygen-dependent degradation domain (ODD) as well as two 
transactivation domains are also recognized: the N-terminal activation 
domain (NAD) and C-terminal activation domain (CAD) (located in the 
Transactivation and stability domain, TAD). The N-terminal transactivation 
domain of HIF-1α and HIF-2α is essential for targeting gene specificity 
[Dyan et al., 2006; Hu et al., 2007], while the CAD contributes to the 
regulation of most, but not all, HIF target genes (figure 10). HIF-α subunits 
heterodimerize with the stable HIF-1β subunit through their HLH and PAS 
domains. HIF heterodimers recognize and bind to hypoxia response 
elements (HREs) in the genome, which are similar to enhancer box (E box) 
motifs and have the consensus sequence G/ACGTG. Genome-wide 
chromatin immunoprecipitation experiments indicated that the correlation 
between HRE occupancy and hypoxic gene induction ranges from high for 
HIF1α upregulated genes to low for both HIF2α induced genes and HIF 
repressed genes [Mole et al., 2009; Xia et al., 2009]. In these latter cases, 
flanking sequences and additional regulatory elements appear to further 
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specify HIF binding and target gene regulation. Recent examples of 
additional modifiers of HIF dependent gene regulation include the forkhead 
box protein A2 (FOXA2) and the chromatin modifier Reptin [Qi et al., 2010; 
Lee et al., 2010].  
 
Figure 10: Schematic representation of HIF-1α and HIF-1β complex                 
[Duffy et al., 2003] 
1.3.2 MECHANISM OF REGULATION 
1.3.2.1 OXIGEN DEPENDENT REGULATION 
The HIF system is subject to a number of complex feedback mechanism. 
Regarding the HIF proteins, ARNT are constitutive nuclear proteins 
whereas the expression and activity of the α subunit is tightly regulated by 
oxygen concentration. It rapidly accumulates upon exposure to hypoxia and 
on reoxygenation is quickly degraded with a half-life of less than 5 min [Yu 
et al., 1998]. Given how detrimental hypoxia is to a cell, this rapid response 
time highlights the speed at which a cell must elicit a reaction to loss of 
oxygen tension. Equally important is the short half-life of the HIF protein 
following reoxygenation, and this time frame suggests that prolonged HIF 
activation might not be beneficial to the cell. The understanding of the 
mechanism that a cell uses to sense hypoxia and conveys this signal to the 
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alpha subunit has greatly increased over the last years. HIF-1α protein 
levels are tightly regulated by several mechanisms, but the most notable of 
these is the degradation pathway. Under aerobic conditions, HIF-1α 
undergoes proteasomal degradation via the ubiquitin-dependent pathway. 
This is due to the recent identification of a family of hydroxylases that 
modify the α subunit in an oxygen dependent manner [Lee et al., 2007]. 
These modifications are mediated by three hydroxylases, known as prolyl 
hydroxylase domain containing proteins (PHD) that posttranslational 
hydroxylate specific proline residues (Pro402 and Pro564) within the ODD 
of HIFα under normoxia [Bruick & McKnight, 2001; Epstein et al., 2001; 
Loboda et al., 2010]. Three PHDs proteins have been identified so far: 
PHD1, 2 and 3 [Epstein et al., 2001]. Although in vitro, all three hydroxylate 
HIF-1α [Bruick and McKnught, 2001], in vivo PHD2 isoform plays a major 
role in normoxic HIF-1α regulation [Appelhoff et al., 2004; Berra et al., 
2003]. The proline hydroxylations are required for the interaction of HIFα 
with the von-Hippel Lindau tumor suppressor gene product (pVHL). pVHL 
serves as the recognition component of E3 ubiquitin-ligase that leads to 
HIFα ubiquitination and 26S proteosomal degradation [Bruick and 
McKnight, 2001; Epstein et al., 2001; Cockman et al., 2000; Maxwell et al., 
1999]. During hypoxia, or in case of lack of PHDs cofactors, PHDs are 
inactive preventing binding of pVHL. Therefore, HIF-1α/2α escape ubiquitin 
and proteasomal degradation and can be transported to the nucleus where, 
after dimerization with HIF-1β and recruitment of numerous coactivators, 
they both bind to the same HRE at the target gene loci [Chilov et al., 1999]. 
HRE has a core of five-nucleotide sequence RCGTG (R:A/G) which is well 
conserved among numerous hypoxia responsive genes [Semenza et al., 
1996]. The inactivation of PHDs during hypoxia and concomitant HIF-1α 
stabilization are also caused by PHDs degradation, which is mediated by 
E3 ubiquitin ligases Siah1a and Siah2 [Nakayama et al., 2004]. The 
mechanism of the PHDs degradation by Siah2 is dependent on p38 and 
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Akt kinases activity. Siah2 is subjected to phosphorylation by p38 that 
increases its activity under hypoxia conditions. Siah2 is upregulated when 
an active form of Akt is introduced in the cells [Nakayama et al., 2007]. 
HIFα subunits are also substrates for an asparaginyl hydroxylase: the 
Factor Inhibiting HIF-1α (FIH1). This enzyme is oxygen-dependent and 
represents another component of the oxygen-sensing machinery. 
Hydroxylation by FIH1 disrupts a critical interaction between HIFα and co-
activators p300/CREB-binding protein (CBP), impairing HIF transcriptional 
activity [Webb et al., 2009; Mahon et al., 2001]. However, FIH1 has other 
targets [Webb et al., 2009; 2009(a)], indicating that it may have HIF-
independent functions as well (figure 11). 
 
Figure 11: Schematic description of the HIF-1α pathway [Akhtar et al., 2014] 
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1.3.2.2 OTHER MECHANISMS OF REGULATION 
Oxygen dependent regulation of HIF-1α degradation involves pVHL, 
however there has been increasing evidence of pVHL independent 
pathways of HIF-1α degradation [Koh et al., 2008; Liu et al., 2007a, 2007b; 
Luo et al., 2010]. Hypoxia-associated factor (HAF), detected both in normal 
and tumor derived cell lines and in proliferating tissues, but undetectable in 
normal non proliferating tissues, has been shown to regulate HIF-1α protein 
stability [Koh et al., 2008]. Koh et al. demonstrated that HAF promotes HIF-
1α degradation independently of cellular oxygen tension. HAF 
overexpression diminishes HIF-1α, whereas HAF knockdown increased 
HIF-1α levels independently of pVHL or oxygen. Interestingly, the HAF 
action is selective for HIF-1α, as neither HAF knockdown nor 
overexpression caused any change in the levels of HIF-2α. This suggests 
that HAF is a novel HIF-1α isoform specific E3 ligase [Koh et al., 2008]. 
Extracellular heat shock protein 90 (Hsp90) is a molecular chaperone 
among whose client proteins is also HIF-1α. Accordingly, HIF-1α stability 
can be regulated by the receptor of activated protein kinase C (RACK1), 
which competes with Hsp90 for binding to HIF-1α and promotes the 
ubiquitination and degradation of HIF-1α in cells exposed to the Hsp90 
inhibitor 17-allylaminogeldanamycin (17-AAG) [Liu et al., 2007a] or the 
calcineurin inhibitor cyclosporine A [Liu et al., 2007b]. Recently, also Hsp70 
and carboxyl terminus of Hsc70-interacting protein (CHIP) were identified 
as HIF-1α interacting proteins that selectively regulate ubiquitination and 
degradation of HIF-1α, but not HIF-2α [Luo et al., 2010]. HIF-1α may also 
undergo other posttranslational modifications. The oxygen-dependent 
degradation of HIF-1α by pVHL can also be mediated by hypoxia induced 
HIF-1α small ubiquitin-like modifier (SUMO)ylation. Interestingly, 
SUMOylation can either positively [Bae et al., 2004; Carbia-Nagashima et 
al., 2007] or negatively [Berta et al., 2007; Cheng et al., 2007] regulate HIF-
1α stability. It was also shown that SUMOylation promotes the binding of 
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pVHL to HIF-1α even when the latter is not hydroxy- lated on Pro402 or 
Pro564 [Cheng et al., 2007]. Recent data showed that also HIF-2α is a 
target protein of SUMO modifier [van Hagen 2009 Loboda]. 
Phosphorylation is another mechanism of HIF-α stabilization. HIF-1α 
undergoes phosphorylation by ERC/microtubule-associated proteins (ERK-
MAPK), resulting in increased  transcriptional activity [Richard et al., 1999]. 
It has been shown that p42/44 and p38 kinase phosphorylated HIF-1α and 
HIF-2α in vitro [Richard et al., 1999; Sodhi et al., 2000], whereas inhibitors 
of these pathway blocked HIF-1α mediated reporter gene expression [Hur 
et al., 2001].  
1.3.3 TRANSCRIPTIONAL CO-ACTIVATORS 
HIF-mediated transcription is dependent on the activity of several 
coactivators, which are recruited to form, together with HIF-α and β, an 
active HIF complex. This process is mediated by transactivation domains, 
the centrally located NAD, and the CAD, situated at the C-terminus end of 
the HIF-α proteins. The data obtained from many studies indicate that the 
p300/CBP is a central integrating coactivator [Arany et al., 1996] which, 
after binding with the HIF-1α or HIF-2α CAD helps to recruit the accessory 
coactivators like steroid receptor coactivator (SRC-1), transcription 
intermediary factor-2 (TIF-2) or the redox factor 1 (Ref-1), a nuclear protein 
possessing both redox and apurinic endonuclease DNA repair activities 
[Xanthoudakis and Curran, 1992]. The coactivators play two main roles: 
stabilizing the transcription initiation complex, that contains the RNA 
polymerase II, and also possessing histone acetyl- transferase activity that 
is required for the polymerase to access DNA within chromatin and 
transcribe it into RNA. SRC-1 and TIF-2 are the members of the SRC-
1/p160 family of transcriptional coactivators harboring histone 
acetyltransferase activity, and are able to interact with HIF-1α and enhance 
its transactivation potential in a hypoxia-dependent manner [Carrero et al., 
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2000]. Ruas and colleagues have found that SRC-1 does not interact 
directly with HIF-1α but is recruited to the complex by CBP in a hypoxia-
dependent manner. By the use of different biochemical assays they 
showed that depletion of CBP from cell extracts abrogated the interaction 
between SRC-1 and HIF-1α [Ruas et al., 2005]. Ref-1 has also been shown 
to be involved in the formation of active HIF complex. Overexpression of 
Ref-1 enhances the transcriptional activity of HIF-1α [Huang et al., 1996] 
and the mechanism of this action relies on the redox-dependent 
interactions between HIF-1α and transcriptional coactivators, including 
p300 and CBP [Carrero et al., 2000]. Ref-1 takes an active part in the 
formation of hypoxia-inducible transcriptional complex regulating the main 
target gene of HIF-1α, the vascular endothelial growth factor (VEGF) 
expression in rat pulmonary artery endothelial cells [Ziel et al., 2004]. 
Interestingly, specific coactivators which bound only HIF-2α have been 
found. For example NF-KB essential modulator (NEMO) is unique for HIF-
2α and enhances HIF-2α mediated transcription activity at normoxia 
[Bracken et al., 2005]. Similarly, the transcription factor Ets1 has been 
demonstrated to interact exclusively with HIF-2α for the transcription of 
VEGF receptor 2 [Elvert et al., 2003]. Another Ets family transcription 
factor, Elk-1, cooperates with HIF-2α to activate the target genes CITED-2, 
erythropoietin (EPO), insulin-like growth factor- binding protein-3 (IGFBP3), 
and plasminogen activator inhibitor-1 (PAI-1) [Aprelikova et al., 2006; Hu et 
al., 2007]. Another group of accessory molecules contains the factors which 
are required for transcription of specific HIF target genes. For example, 
hepatocyte nuclear factor 4 (HNF-4), acting together with HIF-1, is a liver 
and kidney specific transcription factor reported to be obligatory for EPO 
transcription [Zhang et al., 1999]. The deletion mutant of HNF-4, lacking the 
carboxyl terminal transactivation domain, which is essential for protein-
protein interactions with HIF-1α, has been shown to prevent hypoxia 
induction of EPO [Tsuchiya et al., 2002]. The region of the transcriptional 
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coactivators binding is controlled by asparaginyl hydroxylase, also termed 
FIH-1, which was identified as a 2-oxoglutarate and Fe(II) dependent 
oxygenase, similarly as PHDs which modify proline residues in ODD 
domain [Lando et al., 2002]. FIH-1 modified the asparagine 803 of human 
HIF-1α, located in the CAD domain, what lead to blockage of p300/CBP 
coactivators recruitment to HIF-1α. Similarly, FIH-1 is capable of modifying 
the key asparagine residue (N851) within the HIF-2α CAD, thereby 
suppressing its activity [Lando et al., 2002].  
1.3.4 HIF-1Α STABILIZATION IN EXPERIMENTAL MODELS 
The most recent model for oxygen sensing suggests that iron-mediated 
hydroxylation occurs via a group of HIF-specific proline hydroxylases [Yuan 
et al., 2003]. It was suggested that these hydroxylases have an iron 
binding-center and that iron is critical for its enzymatic activity. Epstein and 
colleagues [Yuan et al., 2003] further proposed that iron chelators can 
remove iron from the iron-binding center of the enzyme and that the iron 
can be replaced by cobalt at this site, which inactivates the hydroxylase 
activity. This model is consistent with the observations that cobalt (a 
transition metal) and iron chelators inhibit hydroxylation of HIF. It has been 
well documented that cobalt mimics hypoxia by causing the stabilization of 
HIF-α. The data available in the literature indicated that cobalt is cytotoxic 
to many cell types, including neural cells [Wang et al., 2000; Olivieri et al., 
2001; Yang et al., 2004] and can induce cell death by apoptosis and 
necrosis [Huk et al., 2004]. Cobalt can cause DNA fragmentation [Zou et 
al., 2001; Araya et al., 2002; Graham et al., 2004], activation of caspases 
[Zou et al., 2002], increased production of reactive oxygen species (ROS) 
[Olivieri et al., 2001; Zou et al., 2001; Chandel et al., 2000], augmented 
phosphorylation of mitogen activated protein (MAP) kinases [Yang et al., 
2004; Zou et al., 2002] and elevated levels of p53 [Chandel et al., 2000]. 
Some of the characteristic effects of cobalt are thought to be mediated by 
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interaction with the cellular oxygen-sensing machinery. Like low oxygen 
tension, cobalt at normoxic conditions is able to stabilize the α-subunit of 
hypoxia-inducible factor HIF-1 by blocking its ubiquitination and 
proteasomal degradation [Epstein et al., 2001]. Increased levels of HIF-1α 
result in higher transcription of a set of genes that encode several proteins, 
i.e. glycolytic enzymes, erythropoietin and heat shock proteins, important 
for the adaptation of cells to hypoxic stress [Wiesener et al., 2003; Sharp et 
al., 2004]. Like HIF-1α, the levels of HIF-2α protein are low during normoxia 
and accumulate when cells are exposed to hypoxia, proteasomal inhibitors, 
transition metals (i.e. cobalt), iron chelators, or reducing agents [Yuan et 
al., 2003]. However, the biochemical mechanism by which cobalt stabilizes 
HIF-α remains unknown. A recent model suggested that the hydroxylation 
of HIF-α is mediated by a group of HIF-specific hydroxylases and that 
cobalt can inactivate the enzymes by occupying an iron-binding site on the 
proline hydroxylases [Yuan et al., 2003]. More recently, Yuan and 
colleagues showed that cobalt inhibits the interaction between pVHL and 
hydroxylated HIF-α and that inhibits the hydroxylation of a key proline 
residue within the ODD domain of HIF-2α. This is the first report that cobalt 
stabilizes cellular HIF-2α by occupying the pVHL-binding domain. This 
model suggests that cobalt also stabilizes HIF-α proteins by binding directly 
to the ODD and that cobalt inhibits both hydroxylation and the interaction 
between hydroxylated HIF-α and pVHL. This conclusion is supported by 
MALDI data, which revealed that cobalt binds directly to a synthetic HIF 
peptide with a nonhydroxylated proline residue [Yuan et al., 2003]. In 
addition, results of Yuan and colleagues showed that cobalt inhibits the 
HIF-pVHL interaction even after the proline residue becomes hydroxylated. 
Thus, cobalt can bind to HIF regardless of the hydroxylation state of the 
proline residue within the ODD. The study was carried out in vitro and does 
not necessarily reflect how cobalt functions within cells. One possible 
model to explain how cobalt could stabilize HIF-α in cells is illustrated in 
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figure 12. Cobalt may occupy the iron center of a HIF-α specific proline 
hydroxylase, thereby inactivating the enzyme. Even if a subset of HIF-α 
does undergo hydroxylation, hydroxylated HIF-α could still bind to cobalt. 
Cobalt could thereby prevent the interaction between pVHL and 
hydroxylated HIF-α, which would prevent the subsequent ubiquitination and 
degradation of HIF-α. 
 
Figure 12. Proposed model for oxygen sensing. A, the current model for oxygen 
sensing. The HIF-specific hydroxylase is thought to be an iron-binding protein. In 
the presence of oxygen, it catalyzes the hydroxylation of proline 564 within HIF. 
Hydroxylated HIF is then ubiquitinated by pVHL. Ubiquitinated HIF is degraded by 
proteasomal mechanism. Cobalt inhibits the hydroxylation of HIF by binding to the 
iron-binding domain of HIF hydroxylase. B, revised model based on the new in vitro 
data. Hydroxylation of HIF-α is mediated by a HIF-specific hydroxylase. Cobalt 
binds to the iron center of this enzyme to inactive the hydroxylase activity. Even if a 
portion of HIF-α becomes hydroxylated, cobalt can also bind directly to the 
hydroxylated proteins to prevent the interaction between HIF-α and pVHL, thereby 
preventing the degradation of HIF-α [Yuan et al., 2003] 
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1.3.5 HIF-1Α ACTIVATION DURING KYDNEY TRANSPLANTATION 
During the process of transplantation, organs are subjected to hypoxic and 
ischemic injury at the moment of procurement, preservation and following 
reperfusion. This process of ischemia reperfusion injury (IRI) is recognized 
as being detrimental for organ function and long-term graft survival. In 
particular, in renal transplantation, acute tubular necrosis (ATN) contributes 
significantly to the development of delayed graft function. This has led to 
propose ex vivo machine preservation in attempt to reduce the impact of 
IRI [Moers et al., 2009]. As a consequence, the transplant scientific 
community has focused its attention in order to reducing and ameliorating 
the effects of organ ischemia through different approaches: modulating 
donor management, improving ex vivo organ preservation and minimizing 
reperfusion injury. It is recognized that all mammalian cells have the 
intrinsic ability to sense oxygen and the capacity to activate protective 
genes in the face of hypoxia [Maxwell et al., 1993]. For these reasons, 
better understanding of the role of the HIF pathway in the context of organ 
donation and transplantation could be of importance in improving the 
quality of older and ‘‘high-risk’’ donor organs. Conde and colleagues 
[Conde et al., 2012] have investigated both in the in vitro and in vivo 
settings the effect of stabilizing HIF-1α on the outcomes of IRI models. 
They exposed a proximal tubular HK-2 cell line to a period of 6 h of hypoxia 
and nutrient deprivation to mimic ischemia, followed by re-oxygenation in a 
complete medium as an analogue of reperfusion [Conde et al., 2012]. They 
identified HIF-1α stabilization during hypoxia and again following 3 h of 
reperfusion, with lower signals being detected between the two periods. 
Conde and colleagues [Conde et al., 2012] demonstrated also that the 
response was mediated by an Akt/mTOR signaling pathway and the 
protective effects could be ameliorated by siRNA for HIF-1α or YC-1 (a 
pharmacological inhibitor of HIF-1α). Analysis on biopsies taken during 
transplantation have demonstrated that the HIF system was activated as a 
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result of the procurement process and correlated with the degree of 
exposure of kidneys to warm and cold ischemia [Baan et al., 2003]. 
Rosenberger and colleagues demonstrated, using high-amplification 
immunohistochemistry in human kidney biopsies, that immediately following 
engraftment, HIF-1α was detectable with low HIF detection scores 
correlating with primary nonfunction [Rosenberger et al., 2006]. The 
authors demonstrated that HIF-1α was detectable both in the renal cortex 
and in the medulla with collecting ducts and glomeruli showing a high 
signal. At 2-weeks post engraftment analysis of biopsies showed 
widespread HIF-1α induction and the authors attributed the presence of HIF 
to the effects of posttransplant hyperfiltration, hypertrophy and calcineurin 
inhibitor induced toxicity. At 3 months, HIF expression was no longer 
detectable except in kidneys, demonstrating clinical and sub-clinical 
rejection. The authors hypothesized that the increased HIF expression was 
due to the rejection induced hypoxia. However, inflammatory cell induction 
of HIF remains a possibility, and the relation between HIF levels and 
allograft rejection requires further evaluation. 
1.3.6 HIF-1Α AND VIRAL INFECTIONS 
To control viral and other microbiological infections, the host has developed 
a broad arsenal of innate defense mechanisms, including physical barrier 
functions, soluble effectors such as complement and antimicrobial peptides 
and phagocytic cells. The critical role of phagocytes in host defense lies in 
their rapid mobilization and ability to recognize and inactivate pathogens 
independently of prior encounter, as required by adaptive immunity. The 
principal phagocytes of mammalian innate immunity are cells of the myeloid 
lineage, monocyte/macrophages and neutrophils. These short-lived cells 
are recruited in response to alterations of tissue integrity, whether the 
byproduct of chemical or physical injury or the spread of infectious 
microorganisms [Zinkernagel et al., 2007]. To maintain energy homeostasis 
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and carry out their biological activities in these specialized environments, 
phagocytic cell types must generate adenosine triphosphate (ATP) via 
glycolysis. Because upregulation of virtually every enzyme in the glycolytic 
pathway is mediated almost exclusively by HIF-1α [Semenza et al., 1994], 
a role for this transcription factor in supporting phagocyte function during 
inflammation was intuitive. In the last few years, genetic tools provided not 
only experimental validation of this concept, but uncovered profound 
implications of the HIF-1α control pathway in the overall regulation of 
mammalian innate immunity [Zinkernagel et al., 2007]. Activation of HIF-1α 
pathway during the life cycle of viral pathogens has been the subject of 
various investigation, revealing a diversity of functional outcomes in 
disease progression and critical linkages to viral oncogenesis. Viral 
infection is generally appreciated to induce stabilization of HIF-1α in target 
cells, which consequently contributes to local inflammation. For example, 
the common pathogen of the upper respiratory tract, the respiratory 
syncytial virus (RSV), induces HIF-1α in primary human bronchial epithelial 
cells via a NO-dependent pathway [Kilani et al., 2004]. Increased HIF-1α 
levels stimulate VEGF production, enhancing monolayer permeability, 
which may play a role in the airway edema of acute RSV infection. In some 
cases, HIF-1α may help coordinate a host defense program to limit cell 
damage secondary to viral infection. This scenario might particularly apply 
to viruses which exert an acute cytolytic effect, such as the vesicular 
stomatitis virus (VSV). Several years ago, it was noticed that hypoxia 
reduced the cytopathogenicity and replication of VSV, with measured 
antiviral effects of interferons α and γ potentiated under the low oxygen 
conditions [Naldini et al., 1993]. Interferons in turn have been shown to 
upregulate the expression of HIF-1α [de Veer et al., 2001]. The significance 
of HIF in the antiviral response to VSV was recently established by a 
pharmacological approach for the inhibition of HIF activity by a small 
molecule antagonist (chemotin) or RNA interference enhanced VSV 
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cytotoxicity and replication, whereas the treatment with the hypoxia mimetic 
cobalt chloride promoted cellular resistance to infection [Hwang et al., 
2006]. Furthermore, expression profiling showed HIF enhancement of 
interferon β and other antiviral genes during VSV infection [Hwang et al., 
2006]. For a number of persistent viral infections, when induction of HIF-1α 
is insufficient to conduct the eradication, the accompanying proangiogenic 
program can contribute to oncogenesis. For example, chronic infections 
with the hepatitis B and C viruses (HBV and HCV) are epidemiologically 
associated with the development of hepatocellular carcinoma (HCC), a 
highly vascularized solid tumor. The X protein of HBV (HBx) is felt to play 
an important role in angiogenesis and metastasis of HCC [Wang et al., 
1994]. HIF-1α levels and nuclear translocation are increased in cultured 
liver cells by expression of HBx via p42/p44 mitogen-activated protein 
kinase (MAPK) pathways, leading to transcriptional activation of HIF-1α 
target genes including VEGF, a finding corroborated in vivo in the livers of 
HBx transgenic mice [Yoo et al., 2003]. HBx was found to interact directly 
with the bHLH/PAS domain of HIF-1α, blocking its association with pvHL 
and thus preventing its ubiquitin-mediated degradation [Moon et al., 2004]. 
Moreover, HIF-1α activation induced by HBx was found to increase the 
multi-drug resistance 1 (MDR1) transporter activity in a hepatoma cell line, 
thereby contributing to increase the resistance of the cancer cells to 
chemotherapeutic agents [Han et al., 2007]. Recently, HCV infection has 
also been found to stabilize HIF-1α with contributions from MAPK and other 
cellular activation pathways (NF-kB, STAT-3, PI3-K/AkT), stimulating VEGF 
production and neovascularization in a chick chorioallantioic membrane 
surrogate assay system [Nasimuzzaman et al., 2007]. Another example 
linking viral activation of HIF-1α to proangiongenesis and tumor 
development can be found in the case of human papillomavirus-16 (HPV-
16), the etiologic agent of cervical interstitial neoplasia that, undetected, 
can progress to cervical carcinoma. In advanced cervical cancer lesions, 
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many of which are hypoxic, increased HIF-1α levels can be correlated to 
poor prognosis [Hockel et al., 1996, Birner et al., 2000]. Transfection of 
human cervical cancer cell lines with HPV-16 oncoproteins E6 and E7 can 
induce VEGF expression and capillary formation in vitro; however, this 
proangiogenic effect is abolished when the cells are cotransfected with 
siRNA targeting HIF-1α [Tang et al., 2007]. Together, these new studies 
suggested a synergism of HIF-1α with viral oncogenes in premalignant 
lesions to promote gene activation programs favoring neovascularization 
and cancer development. Increased HIF-1α protein levels and VEGF 
expression are detected in T-cell lines infected with the human T-cell 
leukemia virus type 1 (HTLV-1), via a process involving activation of 
PI3K/Akt signaling by the HTLV-1 protein Tax [Tomita et al., 2007]. The 
major oncoprotein of the Epstein Barr virus (EBV), latent membrane protein 
1 (LMP1), increases HIF-1α levels and stimulates VEGF expression in 
nasopharyngeal epithelial cells through a mechanism dependent both upon 
hydrogen peroxide (H2O2) production and p42/p44 MAPK activity 
[Wakisaka et al., 2004]. Co-immunoprecipation studies indicate EBV LMP1 
enhances the stability of Siah1 E3 ubiquitin ligase, inducing proteasomal 
degradation of PHD-1 and PHD-3 that normally tag HIF-1α for degradation. 
LMP1 thus prevents formation of the VHL/HIF-1α complex, providing a 
mechanism for HIF-1α stabilization during EBV nasopharyngeal cell 
infection [Kondo et al., 2006]. A fascinating crosstalk between viral genes 
and the HIF- 1α pathway has been elucidated for the human herpesvirus 8 
(HHV-8). HHV-8 infection of endothelial cells in vitro leads to increased 
stabilization of the two HIF-α subunits and increased HIF responsive gene 
expression [Carroll et al., 2006]. The HHV-8 latency-associated nuclear 
antigen (LANA), which plays a critical role in modulating viral and target cell 
gene expression, increases HIF-1α mRNA levels, and also physically 
interacts with the transcription factor to enhance its promoter activities [Cai 
et al., 2006]. HIF-1α induction and co-activation during HHV-8 infection can 
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then lead to activation of target genes in the genome of the virus itself,  
which is involved in transition of the virus from latency to a lytic replication 
phase. Another potential example of viral HIF crosstalk, is for the 
parvovirus B19 replication that results enhanced under hypoxic conditions. 
HIF-1α binding to an HRE located in the B19 promoter region can be 
demonstrated; however, the full implications of this finding for viral 
pathogenesis remain unclear [Pillet et al., 2004]. 
1.3.7 HIF-1Α AND HUMAN POLYOMAVIRUS JC 
The recent research above described has highlighted the importance of 
hypoxic response and HIF signaling in controlling immune responses 
towards infectious agents. Like for the other viruses, HIF-1α resulted 
involved also in the activation of JCV, an opportunistic human neurotropic 
polyomavirus that, in case of immunosuppression, can cause the 
Progressive Multifocal Leukoencephalopathy (PML). The first 
demonstration of the mechanism by which JCV crosses the blood-brain 
barrier (BBB) was given by Chapagain and colleagues in 2007 [Chapagain 
et al., 2007]. In particular, they reported that cell-free JCV entry into the 
brain by infecting human brain microvascular endothelial cells and 
replicated efficiently producing infectious virions. JCV is capable to 
promoting cellular stress and is known that several transcription factors 
have been implicated in the activation of the JCV promoter. A work of Piña-
Oviedo and colleagues investigate this aspect and demonstrate the 
implication of HIF-1α in the activation of JCV and the role in the 
development of PML in human oligodendrocytes. HIF-1α was found up 
regulated in glial cells where JCV replication takes place, bizzare 
astrocytes and oligodendrocytes. The increase level of HIF-1α is probably 
due to the response of cellular stress caused by the infection with JCV. 
They observed an up regulation of HIF-1α in endothelial cells from small 
capillaries within areas of demyelination [Piña-Oviedo et al., 2009]. These 
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data, taken together with the discovery of Chapagain and colleagues, lead 
to a novel model to explain the rising of PML: JCV replication in endothelial 
cells in association with the enormous stress of these areas caused by 
demyelinating process are responsible for the up-regulation of HIF-1α in 
these cells. Furthermore, with transcription activation assay they found JCV 
promoter activation by HIF-1α both for the early and the late promoters. 
Interestingly, the activation was potentiated in the presence of Smads 
(pathway downstream effectors of the transforming growth factor-beta TGF-
β), which suggests cooperation between HIF-1α and other proteins in the 
stimulation of JCV transcription and replication. Finally, with others set of 
experiments, they demonstrate the co-localization of HIF-1α and Smads in 
the nuclei of JCV affected glial cells in cases of PML and in vitro, as well as 
their physical interaction by co-immunoprecipitation and the binding of HIF-
1α to the JCV control region by a chromatin immunoprecipitation assay. 
These evidences also open another topic about HIF-1α and JCV latency 
and reactivation. It is well established that after a subclinical primary 
infection, JCV remains in a latent state in the kidney, one of the organs that 
has the capability to detect hypoxia [Beckmann and Shah 1983]. Hypoxic 
conditions can activate glycolysis resulting in the increased synthesis of 
pyrimidines and purines required for JCV viral replication.    
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2. AIM OF THE STUDY 
The human polyomavirus BK (BKV) is a member of the Polyomaviridae 
family detected in 1971 in the urine of an immunosuppressed renal 
transplant recipient who developed ureteric stenosis [Gardner et al., 1971]. 
BKV has a worldwide seroprevalence of about 90%. After the  primary  
infection,  BKV  establishes  a  life-long  latency  within  the  urogenital  
tract.  The  severe  immunological impairment occurring in transplant 
kidney recipients leads to BKV reactivation that may  result  in  the  
polyomavirus  associated  nephropathy  (PVAN).  During  transplantation, 
kidney is  subjected  to  hypoxic  conditions,  driven by  the  action of 
Hypoxia Inducible Factor (HIF). It has been proved that the HIF isoform 1-α 
(HIF-1α) may interact with several viruses, but till now there are no 
evidences regarding  the  interaction between BKV and HIF-1α. In the 
present study, we aimed to achieve a better understanding about the 
relation between BKV infection and hypoxia condition in kidney cells in 
case of transplantation. In order to achieve this aim the experimental 
design of the study was organized as follow: a) analysis of HIF-1α 
expression level in kidney tissues, from both PVAN and not PVAN 
transplanted patients, b) study of the physical interaction between BKV 
promoter (NCCR) and HIF-1α, c) study of the effect of hypoxia on BKV 
replication in an in vitro model of BKV infection. 
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3. MATHERIALS AND METHODS 
3.1 HIF-1Α MRNA EXPRESSION IN PVAN TISSUES 
3.1.1 STUDY PARTICIPANTS AND SAMPLE COLLECTION 
From January 2003 to August 2007, a total of 17 kidney tissue samples 
were collected at the Department of Pathology, Ospedale Maggiore della 
Carità, Novara, Italy at different time points from transplantation. The 
samples were immediately formalin-fixed for a minimum of two hours, 
paraffin-embedded and routinely stained by Hematoxylin & Eosin and 
immunohistochemistry using anti-SV40 antibody (Lee Biomolecular 
Research Labs, San Diego CA) and screened for BKV positivity for 
diagnostic purpose. Patients were divided into three groups, PVAN patients 
(PVAN) that underwent a kidney transplant and developed PVAN after 
transplantation, patients that underwent a kidney transplant without 
developing PVAN (NOT PVAN) and a control group (CTRL) that underwent 
a renal biopsy for a clinical needs/reasons not related to renal transplant. 
The biopsies belonging to the first two groups resulted positive for BKV 
screening, while in the third group all the specimens were negative for BKV 
screening (table 3). The study was performed in accordance with the 
requirements of the local Ethics Committee, and all patients or their 
patients’ parents provided informed consent. 
Table 3.  Case study. PVAN, Polyomavirus Associated Nephropathy; NOT PVAN, 
patients that underwent a kidney transplant without developing PVAN; CTRL, 
control group 
GROUP N° M/F 
AGE 
(years±SD) 
MEAN TIME FROM 
TRANSPLANT 
(months±SD) 
BKV 
PVAN 7 4/3 60.6 ± 10.5 9.2 ± 6.0 + 
NOT PVAN 4 3/1 46.2 ± 13.3 24.5 ± 16.1 + 
CTRL 6 3/3 50.6 ± 20.8 2.4 ± 3.1 - 
48 
 
3.1.2  RNA ISOLATION  
Total RNA was isolated from the paraffin embedded biopsies using the 
RNeasy FFP kit (Qiagen, Germany) according to the manufacturer’s 
guidelines (Appendix C). Total RNA was then quantified using nanodrop 
technology (Thermo Scientific, Lithuania). 
3.1.3 RETROTRANSCRIPTION 
Reverse transcription of total RNA was performed by the QuantiTect 
Reverse Transcription Kit (Qiagen, Germany) according to the 
manufacturer’s guidelines. RNA sample is retrotranscribed using a master 
mix prepared from Quantiscript Reverse Transcriptase (RT), Quantiscript 
RT Buffer, and RT Primer Mix. The entire reaction takes place at 42°C and 
is then inactivated at 95°C. The mix reaction is showed in table 4. cDNA 
was then quantified using spectrophotometric technology (Biorad, USA). 
COMPONENT VOLUME/ REACTION 
Quantiscript Reverse Transcriptase* 1 µl 
Quantiscript RT buffer, 5x** 4 µl 
RT primer Mix 1 µl 
Template RNA ≤ 14 µl (50 ng/l) 
Total volume 20 µl 
Table 4.  Reverse-transcription reaction components. * Contains RNase inhibitor. 
** Includes Mg2+ and dNTPs 
3.1.4 REAL TIME POLYMERASE CHAIN REACTION (REAL TIME 
PCR) 
Real time polymerase chain reaction (Real Time PCR) was performed on 
an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, 
Carlsbad, USA), using the QuantiTect SYBR Green PCR kit (Qiagen, 
Germany) according to the manufacturer’s instructions. The assay was a 
relative quantification of HIF-1α expression compared to the expression of 
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the housekeeping glyceraldehyde-3-phosphate dehydrogenase gene 
(GAPDH), as previously reported [Landry and Mager, 2003]. 
The primer set targeting the HIF-1α and GAPDH genes was previously 
published by Wang and colleagues and Landry and colleagues (table 5) 
[Wang et al., 2014, Landry and Mager, 2003].  
GENE PRIMERS SEQUENCE 
GAPDH 
GAPDH Forward 5'-GCCCAGGATGCCCTTGA-3' 
GAPDH Reverse 5'-GTGTCCCCACTGCCAAC-3' 
HIF-1α 
HIF-1α Forward 5'- TGAAGTGTACCCTAACTAGCCGA -3' 
HIF-1α Reverse 5'- AATCAGCACCAAGCAGGTCATAG -3' 
Table 5. Sequence of GAPDH and HIF-1α primers used in the Real Time PCR 
analysis 
The reaction mix was prepared as follows (table 6): 
COMPONENT VOLUME/ REACTION FINAL CONCENTRATION 
2x QuantiTect SYBR 
Green PCR Master Mix* 
12,5 μL 1x 
Forward Primer (70 μM) 0,11 μL 0,3 μM 
Reverse Primer (70 μM) 0,11 μL 0,3 μM 
Template cDNA 5 μL ( ≤ 500 ng/reaction) 
RNasi-free water 7,3 μL  
Total reaction volume 25 μL  
Table 6. Reaction mix setup. *Provides a final concentration of 2.5 mM MgCl2 and 
containing ROX passive reference dye 
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For both the assays the cycling conditions were as follow (table 7) :  
STEP TIME TEMPERATURE 
UNG* 2 min 50 °C 
PCR initial activation step 15 min 95 °C 
Denaturation 15 sec 94°C 
Annealing 30 sec 54°C 
Extension 30 sec 72°C 
Number of cycles 45  
Table 7. Real Time PCR cycler conditions. *Uracil-N-glycosylase, eliminate any 
resulting from carryover contamination (carryover dUMP-containing PCR 
products prevention) 
3.2  CELL CULTURE CONDITIONS 
African green monkey kidney cell culture (VERO, Amercian Type Culture 
Collection; ATCC) was mantained with Dulbecco’s Modified Eagle Medium 
(DMEM, Euroclone, Italy) supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS) (Euroclone, Italy), antibiotics (50 U/mL penicillin; 50 
μg/mL streptomycin (Euroclone, Italy) and L-Glutamine (2mM) (Euroclone, 
Italy), and icubated at 37°C in a humified environment with 5% CO2. 
3.3 SUBCLONING 
3.3.1 BKV NCCR SUBCLONING 
In a previously study, BKV NCCR (380 bp) Dunlop strain was cloned in the 
BamHI site (G^GATCC) of the pBLCAT3 plasmid. In the present work, BKV 
NCCR was isolated from the pBLCAT3 plasmid by digestion with  BamHI, 
purificated by gel electrophoresis and cloned within the pMetLuc2-Reporter 
vector (Clontech, USA) in early and late orientation in the BamHI site of the 
vector, upstream the coding sequence of the reporter gene Metridia longa. 
For high copy expression of plasmids, the DH5αF’ strain of Escherichia Coli 
(Invitrogen, USA) was transformed with the fresh products of ligation. 
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Plasmid DNA was extracted from bacterial cells using the QIAGEN Plasmid 
Minikit (QIAGEN, Germany) (Appendix A), following the manifacturer’s 
instructions. To confirm the right orientation of the DNA fragments 
automatic sequencing was performed by an external facility (Primm, Italy). 
Sequences were analyzed using BLAST at NCBI. After sequencing two 
clones were choosen with the BKV NCCR linked to the Metridia Luciferase 
(MetLuc) gene in the early (pNCCRLucE) and late (pNCCRLucL) 
orientations respectively (Appendix A).  
3.3.2 HIF-1Α SUBCLONING 
In another previously study, HIF-1α gene was cloned in the BamHI site 
(G^GATCC) of the pcDNA3 vector, a mammalian expression vector with 
the Cytomegalovirus (CMV) promoter and a neomycin-resistance marker. 
The resulting plasmid was named pHIF (Appendix A). 
3.4 LUCIFERASE ASSAY 
Three hundred thousands of VERO cells were seeded in a M6 multiwell 
plate and transiently transfected using FuGENE® 6 Transfection Reagent 
(Promega, USA), following manufacturer’s instructions. 2 μg of each 
plasmid were used for transfection in each well, maintaining the 
FuGENE:DNA ratio 5:2. Cells were transfected with: pNCCRLucE or 
pNCCRLucE co-transfected with pHIF; pNCCRLucL or pNCCRLucL co-
transfected with pHIF; pHIF and pMetLuc2-Reporter vector without BKV 
NCCR inserted. The positive control was constructed using VERO cells 
transfected with pMetLuc2-Control vector (Clontech, USA), containing the 
MetLuc reporter gene transcriptionally regulated by the strong CMV 
promoter. After 48 hours post-transfection cell culture’s supernatant were 
analyzed using Ready-To-Glow Secreted Luciferase Reporter System 
(Clontech, USA) according to the manufacturer’s instructions. Briefly, 5 μL 
of freshly 1X substrate were added to 50 μL of cell culture’s supernatant 
and luciferase activity was assed recording light signal with a Modulus 
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luminometer, according to the manufacturer’s protocol (Turner BioSystems, 
USA). All experiments were performed in triplicates. 
3.5  CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY 
Two million and a half of VERO cells were grown overnight in 100 mm 
dishes and then transiently co-transfected with pHIF plasmid, and with 
pBKV (ATCC) plasmid that contains the whole BKV strain Dunlop genome 
molecularly cloned into the pBR322 vector through its BamHI unique 
restriction site. Briefly, transfection was performed using the FuGENE 6 
transfection reagent (Promega, USA) as previously described. In particular, 
11,5 μg of each plasmid were used for transfection in each dish, mantaining 
the FuGENE:DNA ratio 5:2. Plates were returned to the incubator until 
reaching a 100% confluence. Cells were harvested and used for total 
protein extraction and cross-linking. To evaluate the effective plasmid 
expression, extracted protein were analyzed by western blot targetin HIF-
1α protein (97-120 kDa) and Tubulin protein (46-48 kDa) (Appendix B). In 
parallel, to perform the ChIP assay, cell were cross-linked and 
immunoprecipitated using protein G-Sepharose beads (Protein G Mag 
Sepharose™, GE Healthcare, UK), according to manifacturer’s instructions 
(Appendix B).  
Purified DNA samples obtained downstream the ChIP procedure were 
analyzed through primer-specific PCR set. The primer set spanning the 
BKV NCCR were the following (table 8): 
 NUCLEOTIDE SEQUENCE 
NCCR.F 5082-5102 5’-GATCGAATTCGGCCTCAGAAAAAGCCTCCA-3’ 
NCCR.R 390-411 5’-TATAGGATCCCCCGTCTACACTGTCTTCACC-3’ 
Table 8. Sequence of primers used in the PCR analysis. NCCR.F primer forward, 
NCCR.R primer reverse 
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The reaction mix was prepared as follows (table 9): 
COMPONENT VOLUME/ REACTION 
5x Buffer* 10,0 μL 
dNTPs (10mM) 2,0 μL 
MgCl2 (25mM)* 4,0μL 
NCCR.F (10 pmol/μL) 2,5 μL 
NCCR.R (10 pmol/μL) 2,5 μL 
Taq polymerase (5U/μL)* 0,4 
Template DNA 5 μL 
RNasi-free water 23,6 μL 
Total reaction volume 50 μL 
Table 9. Reaction mix setup. *Promega (USA) 
The amplification was performed on a GeneAmp PCR System 9700 
(Applied Biosystems, USA) running the following protocol (table 10): 
STEP TIME TEMPERATURE 
Initial denaturation 5 min 95°C 
Denaturation 40 sec 95°C 
Annealing 40 sec 60°C 
Extension 40 sec 72°C 
Final extension 5 min 72°C 
Number of cycles 40  
Table 10. PCR cycler conditions. 
The products of amplification were then analyzed after running a 2% 
agarose gel electrophoresis in 0.5X TBE buffer at 90 Volt for 30 minutes 
and stained with GelStar Gel Stain (Lonza Rockland Inc., USA). 
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In parallel, to clarify the nature of the interaction between HIF-1α and BKV 
NCCR, both gene sequences have been in silico analyzed using BLASTN 
2.2.32+ software to find whether one or more HRE core sequences were 
present in the BKV NCCR. 
3.6  BKV INFECTION AND HYPOXIA SIMULATION  
3.6.1 BKV WW URINE PRECIPITATION 
Viral suspension was previously obtained by precipitation from a pool of 5 
human urine samples positive for BKV strain WW virions, using PEG-it 
Virus Precipitation solution (System Biosciences, USA) according to the 
manufacturer’s instructions. No other viruses than BKV strain WW were 
detected by quantitative Real Time PCR (qPCR) analysis in the pooled 
urine samples. PEG-it Virus Precipitation Solution provides a  simple and 
highly effective means to concentrate lentiviral particles. PEG-it is a  
formulation of polyethylene glycol optimized for the precipitation of all 
lentiviral-based particles. Briefly, 1 volume of cold PEG-it Virus Precipitation 
Solution (4ºC) was added to every 4 volumes of urine pool. After an 
incubation at 4°C over night, the solution was centrifugated at 1500 × g for 
30 minutes at 4ºC. After centrifugation, the Lentivector particles may 
appear as a beige or white pellet at the bottom of the vessel. Viral DNA was 
isolated from the lentiviral pellet using the commercial Nucleospin RNAvirus 
kit (Macherey Nagels, Germany), according to themanufacturer’s protocol 
(Appendix C) and tested in a BKV-specific qPCR (Appendix B). Viral stock 
suspension was conserved at -20°C for subsequent infection. 
3.6.2 BKV WW INFECTION 
One million of VERO cells were plated in each T75 flask. After 24 hours, 
cells (at approximately 80% confluence) were infected with 107 copies of 
BKV strain WW stock. The infection was performed by adsorption in serum 
free medium for 90 minutes at 37°C. The inoculum was then removed, cells 
were washed twice with PBS to eliminate unbound virus, and DMEM 
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containing 2% FBS was added. Mock infected cells, that were used as 
negative controls, were given the same treatment, but without the addition 
of virus. After infection with the BKV WW virions, cells were continuously 
cultured in 10% FBS DMEM. The efficiency of viral gene expression and 
viral replication in the infected cell cultures was evaluated by light-
microscope observation of emerging cytopathic effects and by BKV-specific 
qPCR and β-globin qPCR (Appendix B) on DNA isolated from cell cultures’ 
pellets and supernatants, collected at different time-points (days 3, 7, 10 
post infection) and processed with QIAmp DNA blood Mini kit (Qiagen, 
Germany) and NucleoSpin RNA virus kit (Macherey Nagel, Germany) 
respectively, according to the manufacturer’s protocol (Appendix C). The 
detection limit of the BKV qPCR assay was determined at 5 
copies/reaction. Data were expressed as BKV copies per one thousand of 
cells. 
3.6.3 MTT ASSAY 
From the literature is known that cobalt chloride (CoCl2) mimics hypoxia by 
causing the stabilization of HIF-α. To evaluate CoCl2 cytotoxicity, 1,1·104 
VERO cells were seeded in 96-well culture plates and maintained at 37°C 
in a 5% CO2 humidified atmosphere to allow adherence and initiation of 
proliferation. When cells reached ~90% confluence, culture medium was 
removed and CoCl2 containing medium was added to the cells to reach 
final concentrations of 50 μM, 100 μM, 150 μM and 200 μM. Then, cells 
were incubated for 24 hours, 48 hours and 72 hours at 37°C in a 5% CO2 
humidified atmosphere. Culture medium without CoCl2 served as the 
control in each experiment. Cytotoxicity was determined by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) 
(Sigma-Aldrich, Germany) assay. The MTT assay is a colorimetric assay for 
assessing cell metabolic activity. NAD(P)H-dependent cellular 
oxidoreductase enzymes are capable of reducing the tetrazolium dye MTT 
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to its insoluble formazan, which has a purple color. Briefly, at the end of 
exposure periods, 20μL MTT solution (0,5 mg/mL in Phosphate Buffer 
Saline, PBS) were added to the each well, and the cells were incubated 3h 
at 37°C. The dark blue formazon crystals formed in intact cells were 
solubilized with Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, Germany). At 
the end of the incubation, absorbance values of each sample were 
measured at 550 nm using micro plate reader BioTek Synergy™ 4 Hybrid 
Microplate Reader (BioTek, USA). Furthermore, to evaluate the effective 
stabilization on HIF-1α, a western blot analysis targeting HIF-1α protein 
(97-120 kDa) and Tubulin protein (46-48 kDa) was conducted on total 
proteins extracted from CoCl2 treated and untreated cells (Appendix B). 
3.6.4 HYPOXIA SIMULATION 
At day 3 post-infection, corresponding to the viral replication peak level, as 
revealed by BKV-specific qPCR analysis, hypoxic stress was simulated by 
exposing the infected cells to 100μM CoCl2. After 24 hours of exposition, 
cells were collected and nucleic acids were isolated using the QIAmp DNA 
Blood Mini kit (Qiagen, Germany) according to the manufacturer’s 
instructions (Appendix C). This test was performed in duplicate, and 
included a control of infected cells non subjected to CoCl2 treatment. BKV 
and β-globin gene were quantified by specific qPCR assays (Appendix B). 
3.7 STATISTICAL ANALYSIS 
Analysis of HIF-1α qPCR results were analysed by the 2-ΔΔCt method and 
expressed as fold of difference between HIF-1α and GAPDH.  
Results of luminometric assays and MTT assay were expressed as means 
± standard deviation. 
For statistical comparison, significance was evaluated using the Student t 
test. Values of p < 0.05 were considered statistically significant. 
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4. RESULTS 
4.1 HIF-1Α MRNA EXPRESSION IN PVAN TISSUES 
To evaluate HIF-1α expression level in vivo and its cellular behavior in the 
process of transplantation, 17 kidney paraffin-embedded tissue samples 
from BKV+ PVAN patients (tissues from kidney transplant patients who 
developed PVAN after transplantation), BKV+ NOT PVAN patients (tissues 
from kidney transplant patients who did not developed PVAN after 
transplantation) and a BKV- control group (group that underwent a renal 
biopsy for clinical needs/reasons not related to renal transplant) were 
collected. Total RNA was extract from paraffin embedded tissues, reverse 
transcripted into cDNA and analyzed in a qualitative Real Time PCR to 
evaluate HIF-1α expression, compared to GAPDH expression. The mRNA 
expression levels of HIF-1α gene in PVAN tissues and NOT PVAN tissues 
were presented in comparison with the control group. Analysis of Real Time 
PCR data were conducted with the 2-ΔΔCt method and expressed as fold 
differences between HIF-1α and GAPDH. Expression level resulted 13.6 
folds higher in PVAN tissues than its expression in the control group. No 
differences were observed in the HIF-1α expression between the NOT 
PVAN and the control group (figure 13). These results show that HIF-1α is 
stabilized in PVAN tissue BKV positive. 
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Figure 13. Fold differences of HIF-1α mRNA expression in the groups of study. 
CTRL: control group. PVAN (BKV+): Polyomavirus Associated Nephropathy 
samples. NOT PVAN (BKV-): tissue samples not showing Polyomavirus 
Associated Nephropathy 
After these in vivo evidences, the study was designed to evaluate the 
interaction between HIF-1α and BKV in an in vitro model. The first step was 
setted up to evaluate the potential functional interaction between HIF-1α 
and BKV NCCR performing a Luciferase assay. After this, we performed a 
ChiP assay to evaluate a possible interaction between HIF-1α and BKV 
NCCR. At the ends, we create an in vitro model of hypoxia and BKV 
infection to corroborate the previously results. 
4.2 LUCIFERASE ASSAY 
Different sets of luminometric assays were performed to determine the 
potential involvement of HIF-1α in the regulation of BKV NCCR with both 
early and late orientations. BKV NCCR (Dunlop strain) was cloned in the 
BamHI site of pMetLuc2-reporter vector (Clontech, USA) in early and late 
orientation and HIF-1α gene was cloned in the BamHI site of the pcDNA3 
vector. The resulting vectors were named respectively: pNCCRLucE, 
pNCCRLucL and pHIF. These plasmid where used to transiently transfect  
VERO cells with the following setting: pNCCRLucE or pNCCRLucE co-
transfected with pHIF; pNCCRLucL or pNCCRLucL co-transfected with 
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pHIF; pHIF and pMetLuc2-Reporter vector without BKV NCCR inserted. 
The positive control was constructed using the VERO cells transfected with 
pMetLuc2-Control vector (Clontech, USA), containing the MetLuc reporter 
gene transcriptionally regulated by the strong CMV promoter. After 48h of 
incubation, supernatants of transfected cells were used to asses luciferase 
activity. As shown in figure 14, experimental results demonstrated that the 
transcriptional activity of both NCCR early and late configurations was 
enhanced by HIF-1α. Interestingly, in the presence of HIF-1α plasmid, 
transcriptional activity of the BKV NCCR early was increased 6-folds 
(p<0.05), while the BKV NCCR late activity was increased 2-folds (p<0.05) 
respect BKV NCCR early and late activity alone. These result show that the 
presence of HIF-1α stabilize BKV NCCR  increasing its activity as promoter 
of Metridia Luciferase gene indicating a functional interaction between HIF-
1α and NCCR. 
 
Figure 14. Luciferase assay results showed as average luminescence (RLUs). 
HIF: pHIF plasmid. BKV NCCR e: pNCCRLucE plasmid. BKV NCCR L: 
pNCCRLucL plasmid. pMetLuc2-resporter: pMetLuc2-resporter vector without BKV 
NCCR insert. pMetLuc2-control: pMetLuc2-control vector containing the MetLuc 
reporter gene transcriptional regulated by CMV promoter 
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4.3 CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY 
Once the activation of BKV NCCR by HIF-1α was established, a ChIP 
assay was conducted to determine whether HIF-1α binds the BKV NCCR in 
vitro. VERO cells were transiently co-transfected with pHIF plasmid and 
pBKV plasmid (pBR322 vector containing the entire genome of BKV strain 
Dunlop in BamHI site). After reaching 100% confluence, cells were 
harvested and used in parallel for total protein extraction and ChIP assay. 
Proteins were analyzed in a western blot targeting HIF-1α protein and 
Tubulin protein. Western blot analysis confirmed that HIF-α protein is 
stabilized  in the presence of BKV plasmid. Autoradiography film showed 
that HIF-1α signal is slightly present in the lane corresponding to the mock 
control not transfected. In transfected cells, HIF-1α signal resulted 
moderate in the lane corresponding to VERO cells transfected with pBKV 
Dunlop plasmid alone while a stronger signal is present in the lane 
corresponding to VERO cells transfected with pBKV Dunlop plasmid and 
pHIF plasmid. Tubulin signal resulted comparable in all the lanes (figure 
15). 
 
Figure 15. Western blot on protein lysate from transfected cells. MOCK: VERO 
cells not transfected. pBKVDunlop: VERO cells transfected with pBKV Dunlop 
plasmid. pBKVDunlop + pHIF: VERO cells transfected with pBKV Dunlop plasmid 
and pHIF plasmid 
Purified DNA obtained downstream the ChIP procedures were analyzed in 
a PCR specific for BKV NCCR. A 490 bp PCR product, corresponding to 
the BKV NCCR, was detectable in the lanes corresponding to the cross-
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linked and sonicated chromatine before (IP input) and after (IP anti-HIF-1α) 
immunoprecipitation assay, respectively. The same PCR fragment was not 
visible when using the non-specific anti-mouse IgG (mouse IgG control) or 
in the negative control without any antibody (beads only control) (figure 16). 
This result show that there is a physical interaction between HIF-1α and the 
BKV NCCR. 
 
Figure 16. PCR results on 2% agarose gel. Approximate size of the PCR product: 
490 bp. Lane 1: DNA ladder (100 bp). Lane 2: DNA cross-linked and sonicated 
before immunoprecipitation. Lane 3: DNA cross-linked and sonicated after 
immunoprecipitation with the specific mouse monoclonal anti-HIF-1α antibody. 
Lane 4: immunoprecipitation negative control with a non-specific mouse IgG. Lane 
5: no specific antibody used as another negative control. Lane 6: negative PCR 
control. Lane 7: positive PCR control (pBKVDunlop) 
Finally, BLASTN analysis showed no match between HRE sequence and 
BKV NCCR sequences demonstrated that no binding sites for HIF-1α are 
present, confirming what have been previously described in literature. 
4.4 MTT ASSAY 
Before achieving the last step of the study, an MTT assay was performed to 
evaluate the CoCl2 toxicity in VERO cells. VERO cells were treated with 
increasing concentration of CoCl2 and subjected to different time of 
incubation. In particular, cells were treated with 50 μM, 100 μM, 150 μM 
and 200 μM of CoCl2 for 24h, 48h and 72h at 37°C in a 5% CO2 humidified 
atmosphere. MTT assay revealed that CoCl2 reduced the number of viable 
cells in a concentration and time-dependent manner. As shown in figure 17, 
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at 24 hours of incubation, all doses of CoCl2 showed a modest cytotoxicity. 
High concentration of CoCl2 (100 μM, 150 μM and 200 μM) were 
significantly cytotoxic at 48 and 72 hours of incubation. Lower concentration 
of CoCl2 (50 μM) showed a moderate cytotoxicity that slightly reduce cell 
viability in all the time points tested. For these regions, incubations with 100 
μM of CoCl2 for 24 hours and 50 μM of CoCl2 for 48 hours were then 
chosen for the subsequent experiments. 
 
Figure 17. Cell viability of VERO cells determined by MTT assay after treatment 
with increasing dose of CoCl2 at different time of incubation  
Furthermore, to investigate if CoCl2 stabilize HIF-1α protein, a western blot 
analysis on protein extracted from VERO cells treated with 100 μM of CoCl2 
for 24 hours and with 50 μM was conducted. Western blot results confirmed 
that CoCl2 stabilized HIF-α protein in both the CoCl2 treatment (figure 18). 
In particular, incubation with 100 μM of CoCl2 for 24 hours showed a slightly 
intense HIF-1α protein signal. For this reason, in accordance with MTT 
results and experimental conditions, incubation with 100 μM of CoCl2 for 24 
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hours was considered the optimal treatment for the subsequent 
experiments. 
 
Figure 18. Western blot results. 1: VERO cells not treated with CoCl2. 2: VERO 
cells treated with 100 μM of CoCl2 for 24 hours. 3. VERO cells treated with 50 μM 
of CoCl2 for 48 hours 
4.5 BKV INFECTION AND HYPOXIA SIMULATION 
To obtain an in vitro model of infection, VERO cells were infected with BKV 
strain WW virions, previously isolated from a pool of human urine. The 
isolated fraction was tested in a qPCR assay targeting the most frequent 
human polyomaviruses and no other viruses than BKV strain WW were 
detected. In particular, the BKV viral load resulted 5,0·108 viral copies/mL. 
The efficiency of viral replication in infected cell cultures was evaluated by 
light microscopy at days 5 and 10 post infection and by qPCR specific for 
BKV and β-globin gene on nucleic acids extracts from cellular pellet and 
cellular supernatants at days 3, 7, 10 post infection. Light microscopy 
analysis showed that at days 5 and 10 post infection no relevant cytopathic 
effects were detectable. The infected cells looked healthy and didn’t show 
any morphological change (figure 19). These data were in accordance with 
qPCR results that showing an infection peak at day 3 post infection 
(1,27·105 viral copies/mL) in the cellular pellet that rapidly decrease after 7 
and 10 days post infection (3,62·103 and 3,34·102 viral copies/mL 
respectively) (figure 20). qPCR on cellular supernatants showed that BKV 
genome was detectable only at day 3 post infection with a viral load of 
2,44·105 viral copies/mL (data not shown). Negative control of infection 
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resulted negative for morphological changes and for virological qPCR 
screening at the same time points. At day three post infection, 
corresponding to the viral replication peak, cells were treated with 100 μM 
of CoCl2. After 24h of incubation nucleic acids were extract from cellular 
pellet and tested in a qPCR specific for BKV and β-globin gene. Data 
obtained by qPCR experiment reveled that BKV viral load was 3.1 
virions/1000 cells in not treated cells and 15 virions/1000 cells in treated 
cells. In particular, the mean viral load resulted 5-folds increased in CoCl2 
treated cells compared to not treated infected cells (figure 21). 
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Figure 19. Light microscopy analysis. A1: VERO cells not infected (negative 
control NTC) at day 5 post infection, magnification 10X.  A2: NTC at day 5 post 
infection magnification 20X.  B1. VERO cells infected with BKV WW at day 5 post 
infection, magnification 10X. B2: VERO cells infected with BKV WW at day 5 post 
infection, magnification 40X. C1: VERO cells infected with BKV WW at day 10 post 
infection, magnification 10X. C2: VERO cells infected with BKV WW at day 10 post 
infection, magnification 40X 
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Figure 20. Mean viral load (copies/mL) determined by qPCR analysis on DNA 
extracted from cellular pellets and normalized on β-globin gene at days 3, 7 and 10 
post infection 
 
 
Figure 21. Viral load/1000 of infected cells after CoCl2 treatment. Mean viral load 
resulted 5-folds increased in CoCl2 treated cells compared to not treated infected 
cells 
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5. DISCUSSION 
The human polyomavirus BK (BKV) is a member of the Polyomaviridae 
family detected in 1971 in the urine of an immunosuppressed renal 
transplant recipient who developed ureteric stenosis; the virus was named 
as the initials of the patient, BK [Gardner et al., 1971]. Polyomaviruses are 
nonenveloped viruses with an icosahedral capsid of about 40-45 nm in 
diameter. BK virions consist of 88% proteins and 12% DNA. BKV and the 
strictly related JC polyomavirus (JCV) were the first human viruses isolated 
that strongly resembled the morphology and genomic organization of the 
previously described oncogenic polyomaviruses simian virus 40 (SV40) and 
mouse polyomavirus. The viral genome is composed by a single copy of a 
circular double-stranded DNA molecule of about 5 kilobase pairs [Khalili 
and Stoner, 2001]. The genome can be divided into three functional 
regions: the genetically conserved early and late regions and a 
hypervariable regulatory region called Non Coding Control Region (NCCR) 
that contains the bidirectional promoter for both the early and late regions 
[Cole and Conzen, 2001; Moens and Rekvig, 2001]. The early region 
encodes for the two viral regulatory proteins: the large tumor antigen (T-Ag) 
and the small tumor antigen (t-Ag). The late coding region, expressed only 
after the initiation of DNA replication, contains the genetic information for 
the major capsid protein VP1 and the two minor capsid proteins, VP2 and 
VP3 and for a small protein called agnoprotein. Serological surveys have 
shown that BKV infection is widespread in the general population with type-
specific antibodies detectable in 60-80% of healthy adults [Taguchi et al., 
1982] [Knowles et al., 2003; Egli et al., 2009; Antonsson et al., 2010]. 
Natural BKV transmission is not resolved, but likely occurs via the 
respiratory or fecal-oral route [Hirsch et al., 2003] and the primary infection 
occurs predominantly during childhood. After the primary infection, often 
asymptomatic, no defined clinical presentations have been attributed, 
although fever and non-specific upper respiratory symptoms have been 
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suggested [Reploeg et al., 2001]. BKV establishes a life-long subclinical 
latency mostly within the kidney, the urogenital tract and probably also in B 
lymphocytes and other body district of immunocompetent individuals 
[Dörries et al.,1997; Shah 1996; Dolei et al., 2000; Dörries et al.,1994]. 
Intermittent or chronic BKV reactivation can occur in individuals with 
perturbed immune conditions leading to different symptomatology with 
various degrees of severity. Reactivation of BKV can occur in up to 60% of 
healthy pregnant woman, eldery or immune deficient subjects, leading to 
asymptomatic viruria [Hirsch 2005; Tsai et al., 1997; Kitamura et al., 1990]. 
In immunocompromised patients with relative or absolute cellular 
immunodeficiency, BKV reactivation has been associated with interstitial 
nephritis [Nickeleit et al., 2000], ureteral stenosis in renal allograft recipients 
and late onset of hemorrhagic cystitis in bone marrow transplant patients 
[Major et al., 2001]. BKV has also been detected in a variety of tumors such 
as the carcinoma of the urinary tract, prostate cancer and neuroblastoma 
renewing the interest about the BKV epidemiology Carluccio et al., 2014; 
Flaegstad et al., 1999]. For these reasons, during the recent years, BKV 
has drawn the attention of the scientific and medical communities because 
of its potential to cause human diseases. 
Polyomavirus-associated nephropathy (PVAN) is one of the most common 
viral complications in renal transplant recipients and is an increasingly 
recognized cause of renal transplant dysfunction and graft loss [Costa and 
Cavallo, 2012]. Since the first description of PVAN in 1995, an increasing 
prevalence rate from 1% to 10% has been evidenced [Hirsch et al., 2006]. 
PVAN can lead to kidney graft loss in 10% up to 100% of the cases, 
determining the return in hemodialysis, thus significantly and markedly 
reducing the graft survival. PVAN clinical presentation may be 
inconspicuous and lacks of useful features. Varying degrees of renal 
dysfunction may be observed, such as interstitial nephritis and/or ureteric 
stenosis with ureteric obstruction, hydronephrosis, and sometimes 
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associated urinary tract infections [Costa and Cavallo, 2012]. Progression 
of PVAN leads to eventual deterioration of the kidney graft function. Viral 
replication is the single common feature of all patients at risk of 
nephropathy and it is well known that BKV is the etiological agent of PVAN. 
Most of the cases are preceded by an asymptomatic phase of persistent 
and significant viruria that is typically followed by viremia within few weeks. 
A significant and sustained viremia identifies patients with uncontrolled viral 
replication that may potentially lead to parenchymal injury. Once the virus 
has reactivated, an ascending infection via cell-to-cell spread occurs 
[Meehan et al., 2006; Drachenberg et al., 2003; Nickeleit et al., 2000(a)]. 
The infected cells have an enlarged nucleus with a gelatinous basophilic 
inclusion resulting from accumulation of the newly formed virions 
[Drachenberg and Papadimitriou, 2006]. Lysis of the infected cells results in 
viral seepage into the tubule lumen and urine but also to the interstitium 
and propagation to surrounding cells. Subsequent tubular cell necrosis 
leads to cast formation and denudation of the basement membrane. 
Destruction of tubular capillary walls results in vascular spread of the virus. 
Heterogeneous interstitial infiltration of inflammatory cells as well as 
tubulitis may be absent, intermixed with the active infection, or observed in 
areas that lack cytopathic changes. Collateral damage with necrosis and 
apoptosis of noninfected tubule cells may occur. The resultant effect of 
continued intragraft inflammation, tubular injury, and upregulation of 
profibrotic mediators is allograft dysfunction and loss.  
The intense immunosuppressive therapy required to prevent the organ 
rejection after transplantation, is considered the major risk factor for PVAN 
development [Hirsch et al., 2002]. This condition may predispose to the 
reactivation of the latent BKV, which may cause the necrosis of tubular 
cells and therefore the functional impairment of the kidney [Nickeleit et al., 
2002]. For these reasons, a screening for viral replication is the most useful 
tool for the identification of patients at risk of developing nephropathy, 
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allowing for early intervention, such as the preventive reduction of 
immunosuppression, with improvement of outcome [Costa and Cavallo, 
2012]. Screening for polyomavirus replication presents a high negative 
predictive value (>99%), as in the absence of virus replication PVAN is 
excluded [Mischitelli et al., 2007; Cavallo et al., 2009]. The screening for 
viral replication is also the most important tool for monitoring the response 
to the treatment in patients with diagnosed PVAN.  
The observation that PVAN is rare in transplant recipients of other solid 
organs such as liver, heart and lung, despite exposure to the same classes, 
combination and concentrations of immunosuppressive drugs leads to 
believe that there are some other determinants of disease related to the 
allogenic renal graft, pathogenically important for the PVAN development. It 
has been suggested that ischemic injury during organ implantation might 
play a role in creating the appropriate environment for viral 
reactivation/replication leading to nephropathy [Bohl et al., 2007; Trofe et 
al., 2003]. It is well known that under hypoxic conditions, like those that are 
defined during the ischemic time, cells specifically respond through a finely 
regulated mechanism mediated by the hypoxia inducible factors (HIFs) 
[Loboda et al., 2010]. HIFs take part to a signaling cascade that drives the 
expression of a wide variety of genes essential for the adaptive response to 
hypoxia. HIFs are the master regulators of oxygen homeostasis and play a 
role in the development, postnatal physiology as well as disease 
pathogenesis. Since then, more than 70 target genes regulated directly by 
HIFs have been identified and expression of over hundred genes are 
known to be directly or indirectly influenced by HIF. HIF is a dimer 
composed of 120 kDa oxygen-regulated α-subunit and the constitutively 
expressed 91-94 kDa β-subunit. There are three different isoforms of each 
subunit and HIF1 is the principal regulator of the hypoxic response in the 
mammalian cells [Semenza et al., 1998], able to control more than 100 
genes, suggesting that more than 2% of the human genes may be both 
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directly or indirectly regulated by this factor [Manalo et al., 2005].  HIF-1α, 
which is ubiquitous, is constitutively expressed within cells, but under 
normoxia this protein is targeted for proteosomal degradation. During 
hypoxia, HIF-1α ubiquitination is inhibited and therefore this factor can 
translocate to the nucleus where, after dimerization with HIF-1β and 
recruitment of numerous co-activators, can trigger the transcription of target 
genes. HIF-activated genes include VEGF, which promotes angiogenesis, 
Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase (LDHA), and 
Epo, which induces erythropoiesis. 
During the process of transplantation, organs are subjected to hypoxic and 
ischemic injury at the moment of procurement, preservation and following 
reperfusion. This process of ischemia reperfusion injury (IRI) is recognized 
as being detrimental for organ function and long-term graft survival. In 
particular, in renal transplantation, acute tubular necrosis (ATN) contributes 
significantly to the development of delayed graft function. For these 
reasons, better understanding of the role of the HIF pathway in the context 
of organ donation and transplantation could be of importance in improving 
the quality of older and ‘‘high-risk’’ donor organs. In vitro experiments 
showed that HIF-1α is stabilized during hypoxia and analysis of biopsies 
taken during transplantation have shown that the HIF system was activated 
as result of the procurement process and correlated with the degree of 
exposure of the kidneys to ischemia [Baan et al., 2003]. Finally, Rosenberg 
and colleagues demonstrated that HIF-1α was detectable with low scores 
correlating with primary nonfunction immediately after the engraftment 
[Rosenberger et al., 2006]. The authors showed that HIF-1α was detectable 
both in the renal cortex and in the medulla with collecting ducts and 
glomeruli showing a high signal that disappeared at 3 months. The authors 
hypothesized that inflammatory cells induction of HIF, opening a new side 
of research about the relation between HIF levels and allograft rejection. 
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Because the upregulation of the enzymes in the glycolytic pathway is 
mediated almost exclusively by HIF-1α [Semenza et al., 1994], its role in 
supporting phagocyte function during inflammation was intuitive. In the last 
few years, genetic tools provided not only experimental validation of this 
concept, but uncovered profound implications of the HIF-1α control 
pathway in the overall regulation of mammalian innate immunity 
[Zinkernagel et al., 2007]. Activation of HIF-1α pathway during the life cycle 
of viral pathogens has been the object of various investigation, revealing a 
diversity of functional outcomes in disease progression and critical linkages 
to viral oncogenesis. Viral infection is generally induces stabilization of HIF-
1α in target cells, which consequently contribute to local inflammation. In 
literature there are many examples of viral HIF crosstalk. The first example 
is the respiratory syncytial virus (RSV), that induces HIF1-α in primary 
human bronchial epithelial cells via a NO-dependent pathway [Kilani et al., 
2004]. This scenario might apply to that viruses which exert an acute 
cytolytic effect, such as the vesicular stomatitis virus (VSV). Several years 
ago, it was noticed that hypoxia reduced the cytopathogenicity and 
replication of VSV, with measured antiviral effects of interferons α and γ 
potentiated under the low oxygen conditions [Naldini et al., 1993]. For a 
number of persistent viral infections, when induction of HIF-1α is insufficient 
to conduct the eradication, the accompanying proangiogenic program can 
contribute to oncogenesis. For example, chronic infections of the hepatitis 
B and C viruses (HBV and HCV) are epidemiologically associated with the 
development of hepatocellular carcinoma (HCC), a highly vascularized 
solid tumor [Wang et al., 1994]. Another example linking viral activation of 
HIF-1α to proangiongenesis and tumor development can be found in the 
case of human papillomavirus-16 (HPV-16), the etiologic agent of cervical 
interstitial neoplasia that, if undetected, can progress to cervical carcinoma. 
Increased HIF-1α levels can be correlated to poor prognosis in advanced 
cervical cancer lesions, many of which are hypoxic [Hockel et al., 1996, 
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Birner et al., 2000]. Furthermore, increased HIF-1α protein levels and 
VEGF expression are detected in T-cell lines infected with the human T-cell 
leukemia virus type 1 (HTLV-1) [Tomita et al., 2007] and in nasopharyngeal 
epithelial cells infected by Epstein Barr virus (EBV) [Wakisaka et al., 2004]. 
Finally, HIF-1α was stabilized in endothelial cells infected with Human 
Herpes Virus 8 (HHV-8) and replication of parvovirus B19 was enhanced 
under hypoxic condition due to the binding of HIF-1α to the HRE located in 
the B19 virus promoter [Pillet et al., 2004]. As it happens for the other 
viruses, HIF-1α was involved also in the activation of JCV, an opportunistic 
human neurotropic polyomavirus that, in case of immunosuppression, can 
cause the Progressive Multifocal Leukoencephalopathy (PML). A work of 
Piña-Oviedo and colleagues demonstrate the implication of HIF-1α in the 
activation of JCV and its role in the development of PML in human 
oligodendrocytes. HIF-1α was found up regulated in glial, bizzare 
astrocytes and oligodendrocytes cells where JCV replication takes place. 
The increase level of HIF-1α was probably due to the response of cellular 
stress caused by the infection of JCV. The authors observed an up 
regulation of HIF-1α in endothelial cells from small capillaries within areas 
of demyelination. JCV replication in endothelial cells in association with the 
enormous stress of these areas caused by demielinating process were 
responsible for the up-regulation of HIF-1α. Furthermore, with transcription 
activation assay, they showed the JCV early and late promoter activation 
by HIF-1α. These evidences open the topic about HIF-1α and BKV/JCV 
latency and reactivation. It is well established that after a subclinical 
primary infection, BKV and JCV remains in a latent state in the kidney, one 
of the organs that has the capability to detect hypoxia [Beckmann and Shah 
1983]. Hypoxic conditions can activate glycolysis resulting in the increased 
synthesis of pyrimidines and purines required for BKV and JCV viral 
replication. For these reasons further investigation will be necessary to 
corroborate the information about the interaction between HIF-1α  and JCV 
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promoter and new investigation will be necessary to investigate wether 
there is a similar HIF-1α – BKV crosstalk in renal cells. 
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6. CONCLUSION 
Viral replication is the single common feature of all patients at risk of 
nephropathy, and it is well known that BKV is the etiological agent of 
PVAN. The intense immunosuppressive therapy that is required to prevent 
organ rejection after transplantation is considered the major risk factor for 
developing PVAN [Hirsch et al., 2002]. This condition may predispose an 
individual to reactivation of latent BKV, which may cause necrosis of tubular 
cells and therefore functional impairment of the kidney [Nickeleit et al., 
2002]. However, PVAN is rare in transplant recipients of non-kidney solid 
organs such as livers, hearts and lungs, despite exposure of the patients to 
the same classes, combination and concentrations of immunosuppressive 
drugs. Consequently, some other determinants of disease related to the 
allogenic renal graft may be pathogenically important for PVAN 
development. It has been suggested that ischemic injury during organ 
implantation might play a role in creating the appropriate environment for 
viral reactivation/replication that leads to nephropathy [Bohl et al., 2007; 
Trofe et al., 2003]. It is well known that under hypoxic conditions, such as 
those experienced during the ischemic period, cells specifically respond 
through a finely regulated mechanism mediated by the HIFs [Loboda et al., 
2010]. HIF-1α, which is ubiquitous, is constitutively expressed within cells, 
but under normoxia this protein is targeted for proteasomal degradation. 
During hypoxia, HIF-1α ubiquitination is inhibited allowing this factor to 
translocate to the nucleus where, after dimerization with HIF-1β and 
recruitment of numerous co-activators, it can trigger the transcription of 
target genes. HIF-activated genes include VEGF, which promotes 
angiogenesis, Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase 
(LDHA), and Epo, which induces erythropoiesis. HIF-1α may also influence 
the replication of several viruses. A recent study demonstrated the 
important role of HIF-1α in the activation of the JCV promoter [Piña -Oviedo 
76 
 
et al., 2009]. In particular, Piña -Oviedo and colleagues provided evidence 
of direct binding between HIF-1α and the JCV control region and of the 
ensuing early promoter activation. Hypoxic conditions may increase the 
expression of an immediate early protein of Epstein - Barr virus (EBV), thus 
mediating the switch to a lytic form of infection in cells latently infected with 
the virus [Kondo et al., 2006]. In addition, it has been demonstrated that low 
levels of oxygen can up-regulate the replication of human parvovirus B19 
[Pillet et al., 2004] and that HIF-1α is highly expressed in Human T cell 
leukemia virus type 1 (HTLV-1) infected cells [Tomita et al., 2007]. Based 
on the observation that the HIF-1α mRNA expression level was up-
regulated almost 14-fold in the PVAN kidney biopsies compared to both 
BKV positive non PVAN kidney tissues and normal kidney tissues, we 
attempted to find an explanation for these results by a series of in vitro 
experiments. We demonstrated the functional interaction between HIF-1α 
and the BKV promoter because both the early and late viral NCCR were 
up-regulated in conjunction with the over-expression of HIF-1α. This effect 
was probably due to a physical interaction between the BKV NCCR and 
HIF-1α, as shown by the results of the ChiP assay. To finally corroborate 
the findings collected so far, we designed an in vitro model of infection and 
hypoxia resembling as effectively as possible what really occurs in the 
human body. Aiming to optimally simulate an in vivo infection, this model 
was examined using virions directly pooled from human urine samples and 
belonging to the BKV archetypal strain (WW). The normalized viral load 
was determined after hypoxia simulation, demonstrating that HIF-1α 
stabilization induces a 5-fold increase in the viral replication rate. Several 
conclusions can be drawn based on these observations. Patient 
determinants that increase the risk for PVAN may include increased older 
age. In contrast, controversial data are present in the literature regarding 
age-related HIF-1α expression. Liu and colleagues demonstrated that HIF-
1α mRNA levels were significantly greater in young mice compared to 
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mature mice. On the contrary, impaired HIF-1α activation is also observed 
in hypoxic skin wounds of aged diabetic mice [Liu et al., 2008], and 
Rosenberger et al. [2007] showed that HIF-1α levels are higher in older 
kidneys. These findings underscore the importance of aging as a modulator 
of ischemic responses and may perhaps partially explain the findings in the 
cohort of patients we studied because the average age of the recipients 
with PVAN was 60.6 years, while the average ages of the recipients with no 
PVAN and the control group were 46.2 and 50.6 years, respectively. 
Additionally, Rosenberger and colleagues [2007] observed a strong 
correlation between the abundance of HIF-1α and the time elapsed since 
the transplant. In our cohort of patients, this correlation could not be 
confirmed, because in the control BKV negative group of patients, low 
levels of HIF-1α mRNA were observed at a mean time of 2.4 months after 
the transplant; on the contrary in the PVAN BKV positive group of patients, 
high levels of HIF-1α mRNA were observed at a mean time of 9.0 months 
after the transplant. This observation could further corroborate the 
association between the virus and HIF-1α and their synergetic involvement 
in the development of PVAN. Regarding the physical interaction of HIF-1α 
with the NCCR DNA, to the best of our knowledge, no known binding sites 
for HIF-1α have been previously described. The BKV NCCR strain WW and 
Dunlop sequences have been analyzed in silico using BLASTN 2.2.32+ 
software to determine whether one or more HRE core sequences are 
present. (5’-[A/G]CGT-3’) [Wenger et al., 1997]. However, no match was 
found between the HRE sequence and BKV NCCR sequences (data not 
shown); therefore, further functional analyses should be conducted in the 
future to better understand the link between the BKV promoter and HIF-1α. 
These data, taken together, are important in defining the role of hypoxic 
stress in BKV re-activation after renal transplantation. In particular, it can be 
concluded that opportunistic viral replication, which is mainly due to 
immunosuppressive therapy, is further stimulated and favored by HIF-1α 
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activation that is driven by hypoxic conditions during transplantation. The 
experimental results obtained suggest a hypothetical molecular mechanism 
underling this thesis, which can be outlined as follows: the cellular response 
to a hypoxic environment prevents HIF-1α proteasomal degradation, 
allowing the binding of HIF-1α to HIF-1β. The HIF-1 active complex can 
translocate to the nucleus, where it binds to the BKV NCCR, thus 
promoting the transcription of viral genes and stimulating BKV replication. If 
confirmed by further experiments, this scenario may have important clinical 
implications: exposure to hypoxia during the renal transplantation process 
should be considered a crucial risk factor for the development of PVAN. 
These findings could be translated into clinical practice by replacing 
modulation of the HIF system with ex-vivo organ preservation technologies, 
such as extra-corporeal membrane oxygenation [Akhtar et al., 2014], or by 
considering HIF-1α as a target for inhibition, perhaps using RNA 
interference technology. 
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APPENDIX A – MOLECULAR CLONING 
A.1 pNCCRLucE AND pNCCRLucL CREATION 
In a previously study, BKV NCCR (380 bp) Dunlop strain was cloned in the 
BamHI site (G^GATCC) of the pBLCAT3 plasmid. In the present work, BKV 
NCCR Dunlop strain was isolated from the pBLCAT3 plasmid by digestion 
with BamHI, purificated by gel electrophoresis and cloned within the 
pMetLuc2-Reporter vector (Clontech, USA) in early and late orientation in 
the BamHI site of the the multiple cloning site of the vector (nt 48-85), 
upstream the coding sequence of the reporter gene Metridia longa. 
A.2 pBLCAT3 DIGESTION 
The digestion reaction mix was prepared as follow: 
COMPONENT VOLUME/ REACTION 
NEB buffer (10x)* 2,0 μL 
BamHI-HF (10U/μL)* 1,0 μL 
pBLCAT3 plasmid (~1μg/μL) 2,0 μL 
DNAsi-free water 15,0 μL 
Total volume 20 μL 
Table A1. Digestion reaction mix setup. * New England Biolabs 
The reaction was incubated at 37°C over night. 
The product of digestion was analyzed after running a 2% agarose gel 
electrophoresis in 0.5X TBE buffer at 90 Volt for 30 minutes and stained 
with GelStar Gel Stain (Lonza Rockland Inc., USA). Gel DNA purification 
was performed with the QIAquick Gel Extraction and PCR Purification kit 
(Qiagen, Germany) according to manufacturer’s instructions. 
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A.3  pMetLuc2-Reporter DIGESTION 
pMetLuc2-Reporter is a promoter reporter vector that allows the analysis of 
promoter function in cell-based assays. The vector encodes a sequence-
optimized, secreted luciferase from the marine copepod Metridia longa. The 
24 kDa Metridia luciferase (MetLuc) reporter protein contains a 17 amino 
acid, N-terminal signal peptide that allows efficient secretion of the reporter. 
When a functional promoter is cloned into the MCS, located upstream of 
the MetLuc reporter gene, MetLuc is expressed and secreted into the 
medium surrounding the transfected cells. SV40 polyadenylation signals 
downstream of the MetLuc gene direct proper processing of the 3' end of 
the MetLuc mRNA. The vector backbone contains an SV40 origin for 
replication in mammalian cells expressing the SV40 large T antigen, a pUC 
origin of replication for propagation in E. coli, and an f1 origin for single-
stranded DNA production. A neomycin resistance cassette (Neor) allows 
stably transfected eukaryotic cells to be selected using G418. This cassette 
consists of the SV40 early promoter, the Tn5 kanamycin/neomycin 
resistance gene, and polyadenylation signals from the herpes simplex virus 
thymidine kinase (HSV TK) gene. The vector also contains a synthetic 
transcription blocker (TB), composed of adjacent polyadenylation and 
transcription pause sites, that reduces background readthrough 
transcription. A bacterial promoter (PKanr) upstream of the cassette allows 
kanamycin resistance in E. coli (figure A1).  
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Figure A1. pMetLuc2-Reporter Vector Map and Multiple Cloning Site (MCS) 
The digestion reaction mix was prepared as follow: 
COMPONENT VOLUME/ REACTION 
NEB buffer (10x)* 2,0 μL 
BamHI-HF™ (10U/μL)* 1,0 μL 
pMetLuc2-Reporter vector (500ng/μL) 2,0 μL 
DNAsi-free water 15,0 μL 
Total volume 20 μL 
Table A2. Digestion reaction mix setup. * New England Biolabs 
The reaction was incubated at 37°C over night. 
Digested pMetLuc2-resporter vector was then treated with Calf Intestine 
Phosphtase (CIP) (BioSigma, Italy). CIP nonspecifically catalyzes the 
dephosphorylation of 5´ and 3´ ends of DNA and RNA phosphomonoesters. 
In cloning, dephosphorylation prevents religation of linearized plasmid 
DNA. The enzyme acts on 5´ protruding, 5´ recessed and blunt ends. 
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The reaction mix was prepared as follow: 
COMPONENT VOLUME/ REACTION 
Buffer (10x)* 3,0 μL 
CIP (10U/μL)* 0,5 μL 
Digested pMetLuc2-Reporter vector 20 μL 
DNAsi-free water 6,5 μL 
Total volume 30 μL 
Table A3. Reaction mix setup. * BioSigma 
The reaction was incubated at 37°C for 90 minutes. 
The product of CIP treatment was purified using the QIAquick PCR 
Purification kit (Qiagen, Germany) (Appendix C), according to 
manufacturer’s instructions and then visualized in a 2% agarose gel. 
A.4 LIGATION 
For the insertion of BKV NCCR in the pMetLuc2-Reporter vector digested 
and CIP treated was used the T4 DNA Ligase (Promega, Italy) that 
catalyzes the joining of two strands of DNA between the 5 ́-phosphate and 
the 3 ́-hydroxyl groups of adjacent nucleotides in either a cohesive-ended 
or blunt-ended configuration. 
 
The ligation mix was prepared as follow: 
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COMPONENT VOLUME/ REACTION 
Buffer (10x)* 1,0 μL 
T4 DNA ligase  (5U/μL)* 1,0 μL 
BKV NCCR (15ng/μL) 5,0 μL 
pMetLuc2-Reporter vector (50ng/μL)** 2,0 μL 
DNAsi-free water 11 μL 
Total volume 20 μL 
Table A4. Reaction mix setup. * Promega. ** Previously BamHI digested and CIP 
tretaed  
The reaction was incubated at 16°C over night. 
A.5 PLASIMD AMPLIFICATION 
The ligation product was then used to transform the plasmid into E.coli 
DH5α cells using the heat shock method. 10 μL of ligation reaction were 
added to 1 μL of TCM (100mM Tris-HCl pH7.5, 100mM CaCl2, 100mM 
MgCl2) and added to 50 μL of E.coli DH5α cells in ice. After an incubation 
of 30 minutes in ice, the mixture of chemically competent bacteria and DNA 
is placed at 42°C for 1 minute (heat shock) and then placed back in ice for 
5 minutes. Immediately after, 800 μL SOC media (Bacto-Tryptone 20g/L, 
yeast extract 5g/L, NaCl 10mM, KCl 2,5mM, MgCl2 10mM, glucose 20mM) 
were added and the transformed cells are incubated at 37°C for 1 hour with 
agitation. 100 μL of transformed cells were then plated on Luria-Bertani 
(LB) agar plates (LB Medium + 1,5% agar + kanamycin 30μg/mL for 
selective growth) and incubated at 37°C over night. At the end, one 
bacterial colony is picked up and suspended over night at 37°C in LB broth 
for subsequent plasmid purification.  
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A.6 PLASIMD PURIFICATION 
The extraction of plasmid DNA was carried out using the QIAGEN Plasmid 
Minikit that contains three buffers: resuspending buffer P1, the lysis buffer 
P2 and the neutralization buffer P3 (Qiagen, Germany) (Appendix C). The 
bacterial culture is centrifuged at 3000 rpm for 15 minutes. After pouring off 
the supernatant the pellet is resuspended in 200 μL of buffer P1. The lysis 
is allowed by adding 200 μL of buffer P2 and incubating the resuspended 
pellet for 2-3 minutes. The lysis is stopped by adding 200 μL of buffer P3. 
After centrifugation of the mix at 14000 rpm for 5 minutes at 4°C, the clear 
supernatant is taken and isopropanol is added (1:1) in order to allow the 
precipitation of DNA (-20°C, 1 hour). The reaction is then centrifuged at 
14000 rpm for 5 minutes and the supernatant is removed. The air-drying of 
the pellet is required in order to remove residual isopropanol. The pellet is 
resuspended in DNAsi free water (50 μL-150 μL). 
The resulting plasmids were then sent for sequencing to PrimmBiotech 
(Milano, Italy) in order to asses the presence of the insert using a reverse 
sequencing primer that is complementary to the 5’ region of the Metridia 
reporter gene region into the upstream MCS (5’-
CACGATGTCGATGTTGGGG-3’, nt 183-165). 
A.7 pHIF CREATION 
In another previously study, HIF-1α gene was cloned in the BamHI site 
(G^GATCC) of the pcDNA3 vector, a mammalian expression vector with 
the CMV promoter and a neomycin-resistance marker. The resulting 
plasmid was named pHIF.  
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Figure A2. pcDNA3 Vector Map and insertion site (BamHI) of HIF-1α gene 
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APPENDIX B  
B.1 CHROMATINE IMMUNOPRECIPITATION (ChIP) ASSAY 
Chromatine immunoprecipitation (ChIP) is a technique that permit the 
selective enrichment of a chromatin fraction containing a specific antigen. 
Antibodies that recognize a protein or protein modification of interest can be 
used to determine the relative abundance of that antigen at one or more 
locations in the genome in vivo. Briefly, ChIP assay is composed by a 
cross-linking phase that fix the antigen of interest to its chromatin binding 
site, DNA sonication that renders the chromatin soluble and the 
immunoprecipitation of the chromatine with a specific antibody and 
magnetic beads. In the present study, extracts were subjected to ChIP 
using protein G-Sepharose beads (Protein G Mag Sepharose™, GE 
Healthcare, UK), according to manufacturer’s instructions. The primary 
antibody used in the ChIP procedure was a mouse monoclonal anti-HIF-1α 
(ref. numb. 610959, BD Biosciences, USA) and for negative control a non-
specific non-conjugated goat anti-rabbit IgG (Thermo Scientific, USA). The 
procedure was carried out as follows: 
Cross-linking  
1. Wash twice cells with 5 mL of PBS, trypsinize as appropriate (1 mL 
for 3 min), neutralize trypsin with 10 mL of DMEM and place cells 
into 15 mL conical tube 
2. Centrifuge at 1200 rpm for 10 min 
3. Resuspend cellular pellet in PBS 1%  formaldehyde. Incubate 5 min 
with gently mixing  
4. Quench by adding 50 μL of 2.625 M Glycine (0.125 M final) and 
incubate 5 min 
5. Centrifuge 8 min at 500 g (40C) 
6. Wash pellet with 10 mL ice-cold PBS and spin 8 min at 500 g (40C). 
Repeat 3 times 
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7. Resuspend pellet in 150 μL of FA-lysis buffer (50mM HEPES-KOH 
pH 7.5, 140mM NaCl, 1mM EDTA pH 8,0, 1% Triton X-100, 0,1% 
sodium deoxycholate, 0,1% SDS, protease inhibitor 1X). Incubate on 
ice for 10min 
Sonication 
1. Sonicate DNA by 5 cycles, amplitude 30 for 10 seconds 
2. Add FA-lysis buffer to reach a final volume of 500 μL 
3. Centrifuge 1 min at 8000g (40C). Recovery clarify supernatants 
4. Quantify protein concertation by a spectrophotometer 
 
Immunoprecipitation 
1. Magnetic bead preparation: 
- Dispense 5 μL of magnetic beads (25 μL medium slurry) into a 
1,5 mL eppendorf tube 
- Place the eppendorf tube in the magnetic rack and remove the 
storage solution 
2. Equilibration 
- Add 500 μL binding buffer 
- Resuspend the medium 
- Remove the liquid 
3. Binding of antibody 
- Immediately after equilibration add the antibody solution (1μg of 
antibody/500μL of Binding Buffer) 
- Resuspend the medium and let incubate with slow end-over-end 
mixing for 30 minutes 
- Remove the liquid 
4. Washing 
- Add 500 μL of binding buffer 
- Remove the liquid 
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5. Binding of target protein 
- Add sample (25 μg/500 μL di Binding Buffer) 
- Incubate over night at 4°C with slow end-over-end mixing  
- Remove the non-bound fraction 
6. Wash (perform this step 3 times totally) 
- Add 500 μL of wash buffer 
- Remove the liquid 
7. Elution (perform this step 2 times totally) 
- Add 10 volumes of elution buffer compared to the magnetic 
bead volume (50 μL buffer to 5 μL magnetic beads) 
- Fully resuspend the medium and let incubate for 10 minutes in 
slow end-over-end mixing 
- Remove and collect the elution fraction 
 
At the end of the immunoprecipitation protocol, the immunoprecipitated 
fraction was reverse cross linked. Briefly, 100μL of elution buffer were 
added and the solution was incubated at 65°C for 5h. At the end of the 
incubation, DNA was purified using the QIAquick PCR purification kit 
(Qiagen, Germany) (Appendix C). 
The procedure was carried out in parallel for: 
- IP input: cross-linked sonicated sample, not immunoprecipitated 
- Mouse IgG control:  immunoprecipitated sample using a non-specific 
non-conjugated goat anti-rabbit IgG (Thermo Scientific, USA) 
- Beads only control: immunoprecipitated sample without any antibody. 
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B.2 BKV QUANTITATIVE Real-Time PCR (qPCR) 
BKV quantitative Real-Time PCR (qPCR) was performed using the TaqMan 
chemistry and the 7500 Real Time PCR System (Applied Biosystems, 
USA). The standard curve was obtained after serial dilution of the plasmid 
pBKV, with 10 ng of pBKV corresponding to 109 copies of the viral genome 
(dilutions range: 101 to 104 plasmid copies/μL). The standard curve was 
then used to extrapolate the viral load of each sample. A negative and 
positive controls were included in each run. Each sample was tested in 
duplicate, such as the controls and the standards. Primers and probe were 
designed on a conserved region of the VP1 gene and their sequences and 
positions are shown in table B1: 
PRIMERS nt SEQUECE 
BKV Forward 2511–2531 5’-AGTGGATGGGCAGCCTATGTA-3’ 
BKV Reverse 2605-2586 5’-TCATATCTGGGTCCCCTGGA-3’ 
BKV Probe 2578-2546 
5’FAM-AGGTAGAAGAGGTTAGGGTG 
TTTGATGGCACAG-3’MGB 
Table B1. Sequence of primers and probe used in the qPCR BKV specific 
The reaction mix was prepared as follows (table B2): 
COMPONENT VOLUME/ REACTION FINAL CONCETRATION 
5x Universal PCR 
Master Mix * 
4 μL 1x 
Forward Primer (80 μM) 0,05 μL 0,2 μM 
Reverse Primer (80 μM) 0,1 μL 0,4 μM 
BKV Probe (100 μM) 0,04 μL 0,2 μM 
Viral nucleic acid 5 μL (100 ng/μL) 
DNasi-free water 10,81 μL  
Total reaction volume 20 μL  
Table B2. Reaction mix setup. * Solis BioDyne, Estonia 
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For the assay the cycling conditions were as follow (table B3): 
STEP TIME TEMPERATURE 
Holding stage 2 min 50 °C 
Taq activation 15 min 95 °C 
Denaturation 15 sec 95°C 
Annealing/Extension 1 min 60°C 
Number of cycles 40  
Table B3. qPCR cycler conditions 
B.3 β-GLOBIN QUANTITATIVE Real-Time PCR (qPCR) 
β-globin quantitative Real-Time PCR (qPCR) was performed using the 
TaqMan chemistry and the 7500 Real Time PCR System (Applied 
Biosystems, USA). The standard curve was obtained after serial dilution of 
the pCR2.1-βGlobin plasmid (dilutions range: 102 to 105 plasmid copies/μL) 
The standard curve was then used to extrapolate the load of each sample. 
A negative and positive controls were included in each run. Each sample 
was tested in duplicate, such as the controls and the standards. Primers 
and probe set were previously published by Lo and colleagues [Lo et al., 
1998] and are shown in table B4: 
PRIMERS nt SEQUENCE 
β-globin Forward  5’-GTGCACCTGACTCCTGAGGAG-3’ 
β-globin Reverse  5’-CCTTGATACCAACCTGCCCAG-3’ 
β-globin Probe  
5’FAM-AAGGTGAACGTGAACGTGGA 
TGAAGTTGGTGG-TAMRA3’ 
Table B4. Sequence of primers and probe used in the qPCR β-globin specific 
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The reaction mix was prepared as follows (table B5): 
 
COMPONENT VOLUME/ REACTION FINAL CONCETRATION 
5x Universal PCR 
Master Mix * 
4 μL 1x 
Forward Primer (80 μM) 0,1 μL 0,4 μM 
Reverse Primer (80 μM) 0,1 μL 0,4 μM 
β-globin Probe (100 μM) 0,04 μL 0,2 μM 
Viral nucleic acid 5 μL (100 ng/μL) 
DNasi-free water 10,76 μL  
Total reaction volume 20 μL  
Table B5. Reaction mix setup. * Solis BioDyne, Estonia 
For the assay the cycling conditions were as follow (table B6): 
STEP TIME TEMPERATURE 
Holding stage 2 min 50 °C 
Taq activation 15 min 95 °C 
Denaturation 15 sec 95°C 
Annealing/Extension 1 min 60°C 
Number of cycles 40  
Table B6. qPCR cycler conditions 
B.4 WESTERN BLOT 
Western blotting uses specific antibodies to identify proteins that have been 
separated based on size by gel electrophoresis. The immunoassay uses a 
membrane made of nitrocellulose or PVDF (polyvinylidene fluoride). The 
gel is placed next to the membrane and application of an electrical current 
induces the proteins to migrate from the gel to the membrane. The 
membrane can then be further processed with antibodies specific for the  
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target of interest, and visualized using secondary antibodies and detection 
reagents. The western blot assay was performed as follow: 
Preparation of lysate from cell culture 
 Place the cell culture flask on ice and wash the cells twice with ice-
cold PBS. 
 Aspirate the PBS, then add 1 mL of ice-cold RIPA Buffer (Pierce-
Thermo Scientific, USA) with 2X protease inhibitor (Halt™ Protease 
Inhibitor Single-Use Cocktail 100x) (Pierce-Thermo Scientific, USA) 
 Scrape adherent cells off the dish using a cold plastic cell scraper, 
then gently transfer the cell suspension into a pre-cooled 
microcentrifuge tube 
 Maintain constant agitation for 30 min at 4°C. 
 Centrifuge in a microcentrifuge at 4°C for 30 minutes at 14,000 rpm 
 Gently remove the tubes from the centrifuge and place on ice, 
aspirate the supernatant and place in a fresh tube kept on ice, and 
discard the pellet. 
 Read protein extract concentration with a Bradford Assay 
SDS page 
 Prepare SDS-PAGE gel: stacking gel (30% Acrylamide mix, 1,0 M 
Tris pH 6,8, 10% SDS, 10% APS, TEMED, distilled water), running 
gel 8% (30% Acrylamide mix, 1,5 M Tris pH 8,8, 10% SDS, 10% 
APS, TEMED, distilled water)  
 Mix 30 µg of protein extract to 4 μL of loading dye solution 1x and 
RIPA buffer (final volume 24 μL) and heat at 95°C for 5 min 
 Load  protein into the wells of the SDS-PAGE gel, loading 12 μL of 
protein marker (Colorplus prestained protein marker, Broad range 
(7-175kDa), New England Biolabs, USA) in the first well. 
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 Run the gel for 30 minutes at 50 Volts until the enter of protein in 
the running gel then ramp to 100 V for 4 hours in 1X Running Buffer 
(Tris-Glycine-SDS, TGS) (Biorad, USA) 
Blotting 
 Assemble the transfer sandwich without forming air bubbles in the 
sandwich. The blot should be on the cathode and the gel on the 
anode 
 Place the gel in 1x Transfer Buffer (Tris-Glycine, TG) (Biorad, USA) 
with 200 mL of ethanol (95-100%) and transfer over night in a cold 
room at 45 Volts 
Antibody incubation 
 Briefly rinse the blot in water and stain it with Ponceau solution 
(Sigma-Aldrich, USA) to check the transfer quality 
 Rinse off the Ponceau stain with three washes with TBST 
(900mL H2O milliQ + 100mL TBS 10X + 1mL Tween 20) 
 Block in 5% Non Fat Dry Milk (Euroclone, Italy)  in TBST at room 
temperature for 1 hour 
 Incubate 2 hour at room temperature with the primary antibody 
solutions: purified Mouse Anti-Human HIF-1α (cod. 610959) (BD 
Biosciences, USA), diluted 1:500 in 5% Non Fat Dry Milk in 
TBST; α-Tubulin (DM1A) Mouse moAb (cod. 3873) (Cell 
Signaling Technology, USA), diluted 1:8000 in 5% Non Fat Dry 
Milk in TBST 
 Rinse the blot 3–5 times for 5 min with TBST 
 Incubate 1 hour at room temperature with the HRP-conjugated 
secondary antibody solution: Goat Anti-Mouse IgG Peroxidase 
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Conjugated (Pierce-Thermo Scientific, USA) diluted 1:5000 in in 
5% Non Fat Dry Milk in TBST 
 Rinse the blot 3–5 times for 5 min with TBST 
Development methods 
 Apply the chemiluminescent substrate WesternBright ECL HRP 
substrate (Advansta, USA) and incubate in a dark room for 3 
minutes 
 Capture the chemiluminescent signals using photographic paper 
(Kodac, Portugal)  
 Fix the signal incubating the photographic paper in Developer 
and Fixer solution (Kodac, Portugal) 
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APPENDIX C  
C.1 RNeasy FFPE KIT 
The RNeasy FFPE Kit is specially designed for purification of total RNA 
from formalin-fixed, paraffin-embedded (FFPE) tissue sections. Firstly, all 
paraffin is removed from tissue sections by treating with deparaffinization 
solution. Next, samples are incubated in a lysis buffer, which contains 
proteinase K, to release RNA from the sections. A short incubation at a 
higher temperature partially reverses formalin crosslinking of the released 
nucleic acids, improving RNA yield and quality, as well as RNA 
performance in downstream enzymatic assays. This is followed by DNase 
treatment (Qiagen, Germany) that is optimized to eliminate all genomic 
DNA, including very small DNA fragments that are often present in paraffin-
embedded samples after prolonged formalin fixation and/or long storage 
times. Next, the lysate is mixed with Buffer RBC. Ethanol is added to 
provide appropriate binding conditions for RNA, and the sample is then 
applied to an RNeasy MinElute spin column, where the total RNA binds to 
the membrane and contaminants are efficiently washed away. RNA is then 
eluted in a minimum of 14 μL of RNase-free water. The procedure was 
carried out as follows: 
1. Place the sections in a 1,5 mL microcentrifuge tube  
2. Add 160 μL of Deparaffinization Solution, vortex vigorously for 10 sec, 
and centrifuge briefly to bring the sample to the bottom of the tube 
3. Incubate at 56°C for 3 min, then allow to cool at room temperature 
4. Add 150 μL of Buffer PKD, and mix by vortexing 
5. Centrifuge for 1 min at 11,000 x g (10,000 rpm) 
6. Add 10 μL of proteinase K to the lower, clear phase. Mix gently by 
pipetting up and down 
7. Incubate at 56°C for 15 min, then at 80°C for 15 min 
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8. Transfer the lower, uncolored phase into a new 2 mL microcentrifuge 
tube 
9. Incubate on ice for 3 min. Then, centrifuge for 15 min at 20,000 x g 
10. Transfer the supernatant to a new microcentrifuge tube taking care not 
to disturb the pellet 
11. Add DNase Booster Buffer equivalent to a tenth of the total sample 
volume (16 μL) and 10 μL DNase I stock solution. Mix by inverting the 
tube. Centrifuge briefly to collect residual liquid from the sides of the 
tube 
12. Incubate at room temperature for 15 min 
13. Add 320 μL of Buffer RBC to adjust binding conditions and mix the 
lysate thoroughly 
14. Add 720 μL of ethanol (100%) to the sample, and mix well by pipetting. 
Do not centrifuge 
15. Transfer 700 μL of the sample, including any precipitate that may have 
formed, to an RNeasy MinElute spin column placed in a 2 mL collection 
tube. Close the lid gently, and centrifuge for 15 sec at ≥8,000 x g 
(≥10,000 rpm). Discard the flow-through. Repeat step until the entire 
sample has passed through the RNeasy MinElute spin column 
16. Add 500 μL of Buffer RPE to the RNeasy MinElute spin column. Close 
the lid gently, and centrifuge for 15 s at ≥8,000 x g (≥10,000 rpm). 
Discard the flow-through 
17. Add 500 μL of Buffer RPE to the RNeasy MinElute spin column. Close 
the lid gently, and centrifuge for 2 min at ≥8,000 x g (≥10,000 rpm) to 
wash the spin column membrane. Discard the collection tube with the 
flow-through 
18. Place the RNeasy MinElute spin column in a new 2 mL collection tube. 
Open the lid of the spin column, and centrifuge at full speed for 5 min. 
Discard the collection tube with the flowthrough 
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19. Place the RNeasy MinElute spin column in a new 1,5 mL collection 
tube. Add 14 μL RNase-free water directly to the spin column 
membrane. Close the lid gently, and centrifuge for 1 min at full speed to 
elute the RNA 
C.2 QIAquick PCR PURIFICATION KIT 
The QIAquick system use a spin-column technology with a selective 
binding properties of silica membrane. Buffers provided with each kit are 
optimized for efficient recovery of DNA and removal of contaminants in 
each specific application. DNA adsorbs to the silica membrane in the 
presence of high concentrations of salt, while contaminants pass through 
the column. Impurities are washed away, and pure DNA is eluted with 
DNAsi free water. The procedure was carried out as follows: 
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix 
2. Place a QIAquick spin column in a provided 2 mL collection tube 
3. To bind DNA, apply the sample to the QIAquick column and centrifuge 
at 14,000 rpm for 30–60 s 
4. Discard flow-through. Place the QIAquick column back into the same 
tube 
5. To wash, add 0.75 mL of Buffer PE to the QIAquick column and 
centrifuge at 14,000 rpm for 30–60 s 
6. Discard flow-through and place the QIAquick column back in the same 
tube. Centrifuge the column for an additional 1 min at 14,000 rpm 
7. Place QIAquick column in a clean 1,5 mL microcentrifuge tube 
8. To elute DNA, add 50 μL of DNAsi free water to the center of the 
QIAquick membrane, let the column stand for 1 min and then 
centrifuge the column at 14,000 rpm for 1min 
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C.3 NucleoSpin RNA Virus KIT 
With the NucleoSpin RNA Virus method, RNA and DNA viruses are lysed 
by Lysis Buffer RAV1 solution and Proteinase K digestion. Lysis buffer and 
ethanol create appropriate conditions  for binding of nucleic acids to the 
silica membrane of the NucleoSpin® RNA Virus Columns. Contaminations 
(potential PCR inhibitors) like salts, metabolites and soluble  
macromolecular cellular components are removed in simple washing steps 
with ethanolic buffers RAW and RAV3. The nucleic acids can be eluted in 
DNasi free water and are ready-for-use in subsequent reactions. The 
procedure was carried out as follows: 
 
Lysis of viruses 
- Add 600 μL of Buffer RAV1 without carrier RNA to 150 μL of the 
sample 
- Add 20 μL Proteinase K (20 mg/mL stock solution), to the lysis mixture 
- Pipette mixture up and down and vortex well. Incubate for 5 min at 
70°C 
- Add 600 μL ethanol (96–100%) to the clear lysis solution and mix by 
vortexing (10–15 s) 
 
Bind viral RNA 
- Place NucleoSpin RNA Virus Columns in collection tubes (2 mL) and 
load 700 μL of lysed sample. Centrifuge for 1 min at 8,000 x g 
- Load the residual lysis solution onto the NucleoSpin RNA Virus 
Column. Centrifuge for 1 min at 8,000 x g 
- Discard flow-through and place the NucleoSpin RNA Virus Column into 
another new collection tube (2 mL) (more than two loading steps are 
not recommended) 
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Wash and dry silica membrane 
- Add 500 μL of Buffer RAW to the NucleoSpin RNA Virus Column. 
Centrifuge for 1 min at 8,000 x g. Discard flowthrough 
- Add 600 μL of Buffer RAV3 to the NucleoSpin RNA Virus Column. 
Centrifuge for 1 min at 8,000 x g. Discard flowthrough 
- Place the NucleoSpin RNA Virus Column in a new collection Tube (2 
mL) and add 200 μL of Buffer RAV3. Centrifuge for 2–5 min at 11,000 x 
g to remove ethanolic Buffer RAV3 completely. 
 
Elute viral RNA 
- Place the NucleoSpin RNA Virus Column into a new, sterile 1.5 mL 
microcentrifuge tube 
- Add 50 μL of DNase-free water (preheated to 70 °C) and incubate for 
1–2 min. Centrifuge for 1 min at 11,000 x g 
C.4 QIAamp DNA BLOOD MINI KIT 
The QIAamp DNA purification procedure comprises four steps and is 
carried out using QIAamp Mini columns in a standard microcentrifuge. The 
lysate buffering conditions are adjusted to allow optimal binding of the DNA 
to the QIAamp membrane before the sample is loaded into the QIAamp 
Mini spin column. DNA is adsorbed onto the QIAamp silica membrane 
during a brief centrifugation. Salt and pH conditions in the lysate ensure 
that protein and other contaminants are not retained on the QIAamp 
membrane. DNA bound to the membrane is washed in two centrifugation 
using two wash buffer, Buffer AW1 and Buffer AW2 that improves the purity 
of the eluted DNA. Purified DNA is eluted from the QIAamp column in 
water, previously equilibrated at room temperature. The procedure was 
carried out as follows: 
 
- Pipette 20 μL of Protease K into the bottom of a 1,5 mL microcentrifuge 
tube 
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- Add 400 μL of sample to the microcentrifuge tube 
- Add 200 μL of Buffer AL to the sample. Mix by pulse-vortexing for 15 
sec 
- Incubate at 56°C for 10 min 
- Briefly centrifuge the 1,5 mL microcentrifuge tube to remove drops from 
the inside of the lid 
- Add 200 μL of ethanol (96-100%) to the sample and mix by pulse 
vortexing for 15 sec. After mixing, briefly centrifuge the 1,5 mL 
microcentrifuge tube to remove drops from the inside of the lid 
- Apply the mixture to the QIAamp spin column without wetting the rim 
Close the cap and centrifuge at 6,000 x g (8000 rpm) for 1 min. Discard 
the filtrate and place the QIAamp spin column in a clean 2 mL 
collection tube 
- Add 500 μL of Buffer AW1 without wetting the rim. Centrifuge at 6,000 
x g (8000 rpm) for 1 min. Discard the filtrate and place the QIAamp 
spin column in a clean 2 mL collection tube 
- Add 500 μL of Buffer AW2 without wetting the rim. Centrifuge at full 
speed for 3 min. Discard the filtrate and place the QIAamp spin column 
in a clean 2 mL collection tube 
- Add 50 μL of DNAsi free water. Incubate at room temperature (15-
25°C) for 1 min and centrifuge at 6,000 x g (8000 rpm) for 1 min 
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